Characterization of pathogenicity factors of a lethal influenza A(H1N1)09 pandemic viral isolate by Vasilijevic, Jasmina
 
 
 UNIVERSIDAD AUTÓNOMA DE MADRID 
 
Faculty of Science 
Department of Molecular Biology 
 
 
 
Characterization of pathogenicity factors of a lethal 
influenza A(H1N1)09 pandemic viral isolate 
 
 
 
Doctoral Thesis 
 
Jasmina Vasilijevic 
Madrid 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis presented by Ms. Jasmina Vasilijevic in order to obtain Philosophy Doctoral degree (PhD) in 
Molecular Bioscience at Universidad Autónoma Madrid. 
 
 
 
 
 
 
 
 
Thesis Directors: 
Dra. Amelia Nieto Martín, scientific investigator of Consejo Superior de Investigaciones Cientificas (CSIC) 
Dra. Ana Fálcon, scientific investigator of Consejo Superior de Investigaciones Cientificas (CSIC) 
 
 
 
 
 
 
  
This work have been done at the Nacional Center of Biotechnology (CNB- CSIC) at the department of 
Cellular and Molecular Biology thanks to La Caixa International PhD Fellowship, Plan Nacional de 
Investigacion Científica, Desarrollo e Innovacion Tecnologica (BFU2011-26175 and BFU2014-57797-R) and 
the Ciber de Enfermedades Respiratorias (CIBERES). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Za moju porodicu  
For Carmen and Suresh 
  
 
 
 
 
  
 
 
Acknowledgements 
  
 
 
 
  
 
 
First, I would like to thank my thesis directors Amelia and Ana, who have guided me on this work for the last 3 years, 
helping me make it the way it is today. I thank them for the opportunity to let me grow and learn, think outside the 
box, be creative and teaching me not be afraid to question.  
My thanks to my lab mates (Noelia, Laura, Paloma and Ale) as well, for always being there for me, going out of their 
way in helping me, and for just giving love and support. 
Gema, Victoria, Lidia, Gines and Diego, thank you for making every unbearable day (and you know there have been 
many of them) more bearable and for finding a way to remind me that sometimes what is important above everything 
else is what I believe, think and know. 
Thanks to Lili, Noelia, Silvia and Ernie who helped me more than they could know just by listening. 
Thanks to my crew, my peeps, 241 lab both old and new members. Bea, Massi, Lidi, Evita, Yago, Alex, Victor, Alvarus 
and Luis Angel, who adopted me from the day one, making me feel at home. I can honestly say that you are some of 
the best people I have ever met. I am so grateful for your friendship, your support and genuine care.  Thank you for 
the unforgettable moments, talks and some of my best times spent in CNB - our lunch time together.  
Thanks to my ex 211 lab. Elvita, Noe, Coloms, Clau, Ynes, Jero and Alex.  My first contact with Spanish people, culture 
and my first contact with science. Thank you for making me feel welcome and accepting me from the moment I 
walked in. Thank you for making science fun and amazing, for making me forget about time while working and be 
excited to wake up every morning and go to work. Thank you for the endless talks about everything from Carl Sagans’ 
blue dot, hyper mutant bacterial strains, Rafaels’ english skills in “Aquarius“ to Star Wars films. I loved every moment I 
was part of something great, 211. Mutadores 4ever. 
Thanks to my little Spanish-Indian-Cuban family. You know I would not be able to make it without you. Carmendy, Su, 
Clau and Raj, you are the best part of the last 4 years and at the end, you make it all worth it. Thank you for being 
there every step of the way, pushing me to overcome all the obstacles and to never give up. 
Carmendy and Su, this thesis is as much as yours as it is mine.  If I would have to do everything all over again (and you 
know, you know what that implies) I would do it in a blink of an eye if it would mean having you as my friends. My 
heart and soul goes out to you. I cannot thank you enough, and no words can describe how much I appreciate all that 
you have done.  I am proud to call you my friends, although you are much more than that, you are my family tied by 
kindness, care and love. I wish there were more people like you in the world - what a place it would be! You make it all 
better, you make me better, I love you. 
Za moju porodicu. Kada sam polazila u Madrid, znam da sam jedva čekala da ove 4 godine prodju. U međuvremenu 
sam upoznala neke divne, predivne ljude, pune vrlina, znanja i razumevanja (nekada nisam bila te sreće), stekla 
prijatelje za ceo život i videla i onu drugu, ne tako svetlu stranu ljudi. Zbog svog iskustva koje sam stekla u proteklih 4 
godine želim da vam kažem: 
Nati, mama, tata, liko, dekane i Yahir, 
 
 
Hvala vam sto ste me naučili da budem čovek, dobar čovek, da radim ispravno, govorim šta mislim, da se ne kitim 
tuđim perjem, ne mešam u stvari koje me se ne tiču, ignorišem glupost i poštujem razum. Hvala vam što ste me naučili 
da ne budem nemi posmatrač nepravde, da ne gazim preko drugih da bih zadovoljila svoje sitne potrebe, da nisu svi 
ljudi isti, da biram svoje prijatelje, verujem u sebe, ma šta neki ljudi pričali i da znam da su neznaje i zavist pošast.  
Hvala vam što znate sve ovo i što ste mene i seku naucili da budemo kao vi. Hvala vam što ste uvek bili tu, svaki dan, 
svaki sat, svaki tren. Hvala vam za najlepši život koji ste nam pružili. Ovo nije samo moj uspeh, ovo je vaš uspeh. Volim 
vas sve mnogo, mnogo, mnogo. 
Nati, mama, tata, liko, dekane i Yahir, ovo je za vas. 
  
 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
Table of Content 
Abbreviations ..................................................................................................................... 1 
List of tables and figures ...................................................................................................... 5 
Summary .......................................................................................................................... 11 
Resumen........................................................................................................................... 12 
Introduction ...................................................................................................................... 15 
1. Influenza virus and flu ......................................................................................................................... 17 
2. Structure of influenza A virus .............................................................................................................. 21 
2.1 Hemagglutinin HA ........................................................................................................................ 22 
2.2 Neuraminidase NA ....................................................................................................................... 23 
2.3 Matrix proteins ............................................................................................................................ 23 
2.4 Nucleoprotein NP ........................................................................................................................ 23 
2.5 Non-structural 1 (NS1) and nuclear export (NEP) proteins ......................................................... 24 
2.6 Viral RNA dependent RNA polymerase (vRdRP) .......................................................................... 24 
3. Polymerase subunits and pathogenicity of virus ................................................................................. 25 
3.1 Polymerase basic 2 subunit PB2 .................................................................................................. 26 
3.2 Polymerase basic 1 subunit PB1 .................................................................................................. 27 
3.3 Polymerase acidic subunit PA ...................................................................................................... 27 
4. Generation of defective genomes (DGs) ............................................................................................. 28 
4.1 Effects of DGs during the infection .............................................................................................. 30 
5. Characterization of DGs production in isolates of influenza A viruses from 2009 pandemic ............. 32 
6. Antiviral response in infected cells ...................................................................................................... 33 
6.1 Recognition of PAMPs. First cascade of antiviral response ............................................................... 33 
6.2 Activation of antiviral genes. Second cascade of antiviral response ................................................. 35 
7. Innate immune response upon influenza virus infection .................................................................... 36 
Objectives ......................................................................................................................... 41 
Materials and Methods ..................................................................................................... 45 
I Materials ........................................................................................................................ 47 
1. Cell lines ........................................................................................................................................... 47 
2. Viral strains ...................................................................................................................................... 47 
3. Plasmids ........................................................................................................................................... 47 
4. Bacteria strains ................................................................................................................................ 48 
5. Antibodies ........................................................................................................................................ 48 
6. Mice strains ..................................................................................................................................... 48 
 
 
 
 
7. Other material ................................................................................................................................. 48 
II Methods.................................................................................................................................................... 49 
1. Viral manipulation ............................................................................................................................... 49 
2. Bacterial transformation ..................................................................................................................... 49 
3. DNA and RNA manipulation ................................................................................................................ 50 
4. Protein accumulation analysis ............................................................................................................. 54 
5.  In vivo studies ..................................................................................................................................... 55 
Results .............................................................................................................................. 59 
1. Study of the contribution of changes found in the F viral strain to its pathogenicity in vitro and in 
vivo   ............................................................................................................................................................. 61 
2. Characterization of recombinant viruses containing changes present in the F isolate in mouse 
infection model ........................................................................................................................................... 63 
2.1 Determination of LD50 .................................................................................................................. 63 
2.2 Replication of recombinant viruses in lungs of infected mice .................................................... 66 
2.3 Replication of recombinant viruses in extra-pulmonary organs of infected mice ...................... 68 
2.4 Immune response in lungs of infected mice ............................................................................... 72 
3. Antiviral response in human infected cells ......................................................................................... 76 
4. Role of defective genomes (DGs) in viral pathogenicity ..................................................................... 78 
Discussion ......................................................................................................................... 85 
1. Pathogenesis of influenza virus ........................................................................................................... 87 
1.1. Identification of the main driving mutation of a fatal human virus pathogenesis...................... 88 
1.2 Role of defective genomes (DGs) on viral pathogenesis ............................................................. 90 
1.3 Role of host factors on viral pathogenesis .................................................................................. 93 
1.4. Innate immune response contributes to viral pathogenicity in vivo................................................ 94 
1.5 Viral spread promotes viral pathogenicity in vivo ....................................................................... 97 
Conclusions ..................................................................................................................... 101 
References ...................................................................................................................... 107 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
  
 
 
1 
 
Abbreviations 
 
  
 
 
2 
 
      
 
 
1 
 
aa amino-acid 
A549 human type II alveolar epithelial cells 
AH1N1pdm09 pandemic 2009 A H1N1 virus 
AM Alveolar Macrophages 
Amp Ampicillin 
APC Antigen Presenting Cells 
APDS Acute Pulmonary Distress Syndrome 
AV node Atrioventricular node 
CAL A/California/04/09 virus 
CAL-HA HA S127L A/California/04/09 virus 
CAL-M M1 86S-M2 30N A/California/04/09 virus 
CAL-M/PA M1 86S-M2 30N-PA D529N 
A/California/04/09 virus 
CAL-PA PA D529N A/California/04/09 virus 
CAL-PB2 PB2 A221T A/California/04/09 virus 
CAL-PB2/PA PB2 A221T-PA D529N A/California/04/09 
virus 
CARD Caspase Activation and Recruitment Domains 
Cardif CARD-containing adaptor protein 
CAT Chloramphenicol Acetyltransferase 
Ccl19 Chemokine (C-C motif) ligand 19 
Ccl19 Chemokine (C-C motif) ligand 19 
Ccr5 C-C chemokine receptor type 5(CD195) 
CHD1, 6 Chromodomain Helicase DNA-binding protein 
1, 6 
CLPs C-type Lectin Receptors 
CMP-1 Calmodulin-binding protein 
CNIC Centro Nacional de Investigaciones 
Cardiovasculares 
cRNA Complementary RNA 
Csf3 Colony-stimulating factor 3 
CVB Coxsackievirus B 
Cxcl10 Chemokine (C-X-C motif) ligand 10 (IP10) 
Cxcl11 Chemokine (C-X-C motif) ligand 11 
Cxcl13 chemokine (C-X-C motif) ligand 13 
Cxcl9 Chemokine (C-X-C motif) ligand 9 
DC Dendritic cell 
DGs Defective Genomes 
DIs Defective Interfering RNAs 
DMEM Dulbecco’s modified Eagle’s medium 
DNase DNA ribonuclease 
Dpi Day post-infection 
dsRNA Double -stranded RNA 
ECG Electrocardiogram 
EDTA Ethylenediaminetetraacetic acid 
eIF2α Eukaryotic initiation factor 2α-subunit 
eIF4G Eukaryotic translation initiation factor 4G 
F strain virus isolated from patient with fatal outcome 
FBS Fetal bovine serum 
HA Hemagglutinin 
hCLE/C14orf166 chromosome 14 open reading frame 
166 
 
 
2 
 
HEK293T 293T human embriotic kidney cells 
HIV Human Immunodeficiency Virus 
HPAIV Highly Pathogenic Avian Influenza Viruses 
IAV Influenza A Virus 
IFITMs IFN induced transmembrane proteins 
IFN α Interferon α 
IFNAR IFN-α/β receptor 
IFN-β Interferon β 
IFN-λ1 Interferon λ1 
IL1B Interleukin 1 beta 
IL-6 Interleukin 6 
IL-8 Interleukin 8 
ILs Interleukins 
IP10 Interferon-gamma-inducible protein 10 (Cxcl10) 
IRF3,7,9 Interferon Regulatory Factor  3,7,9 
ISG56 Interferon Stimulated Gene 56 protein 
ISGF3 Interferon Stimulated Gene Factor 3 
ISGs Interferon Stimulated Genes 
ISRE Interferon-Sensitive Responsive Element 
IκB nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor alpha 
Jak1 Janus kinase 
LB Luria-Bertani medium 
LD50 Viral dose that causes 50% of mortality 
LGP2/RLR3 RIG-I-like receptor 3 
LTA Lymphotoxin-alpha(TNF-β) 
Ly6G Lymphocyte antigen 6 complex locus G6D 
M strain virus isolated from patient with mild 
symptoms 
M1 Matrix Protein 1 
M2 Matrix Protein 2 
MAVS Mitochondrial Antiviral Signaling Proteins 
MCP-1 Monocyte Chemoattractant Protein-1 
MDA5 Melanoma differentiation associated factor 5 
MDCK Madin-Darby canine kidney cells 
mDCs myeloid dendritic cells 
mg milligram 
ml milliliter 
MIP-1α Macrophage Inflammatory Proteins 1α 
MIP-1β Macrophage Inflammatory Proteins 1β 
MOI Multiplicity of infection 
MORC3- MORC family CW-type zinc finger 3 
mRNA Messenger RNA 
MxA Myxovirus resistance gene A protein 
MyD88 Myeloid differentiation primary response gene 
88 
NA Neuraminidase 
NEP Nuclear Export protein 
NF-κβ Nuclear Factor kappa-light-chain-enhancer of 
activated B cells 
NK Natural killer cells 
NKT Natural killer T cells 
 
 
3 
 
NLRP3 NOD-LRR-and pyrin domain-containing 3 
nm nanometer 
NOD-LRR Nucleotide-binding Oligomerization Domain 
Leucine-Rich Repeat 
NP Nuclear Protein 
NS1 Non-structural 1 protein 
OAS 2’-5’ olygoadenylate synthetase 
PA Polymerase acidic protein 
PABP1 PolyA binding protein 1 
PAMPs Pathogen Associated Molecular Patterns 
PB1 Polymerase basic 1 protein 
PB2 Polymerase basic 2 protein 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PFU Particle forming units 
PKR Protein kinase R 
PRRs Pathogen Recognition Receptors 
RANTES/Ccl5 Chemokine (C-C motif) ligand 5 
RIG-I Retinoic-acid Inducible Gene I-like receptors 
RIP1 Receptor-Interacting serine/threonine-Protein 
kinase 1 
RLR RIG-I like receptors 
RNA Ribonucleic Acid 
RPM Reads per million 
rRNA  ribosomal RNA 
RSV Respiratory Syncytial Virus 
SA node Sinoatrial node 
SA Sialic acid 
SDS Sodium dodecyl sulphate 
ssRNA Single Stranded RNA 
STAT1,2 Signal Transducer and Activator of 
Transcription 
TBK1 TANK binding kinase 1 
TIR Toll-IL-1 receptor 
TLR 2,3,4,7,8,9 Toll-like receptors 2,3,4,7,8,9 
TNF tumor necrosis factor 
TNF-α Tumor necrosis factor α 
TRAF6 TNF receptor associated factor 
TRIF TIR-domain-containing adapter-inducing 
interferon-β 
TRIM25 Tripartite Motif containing 25 
Tyk2 Tyrosine kinase 
VISA Virus-Induced Signalling Adapter 
vRdR Viral RNA dependent RNA polymerase 
vRNA Viral RNA 
vRNPs Viral Ribonucleoproteins 
wt wild type 
 
  
 
 
4 
 
 
  
 
 
5 
 
 
List of tables and figures 
 
  
 
 
6 
 
 
  
 
 
7 
 
Tables 
 
Table 1. Sequence of specific site-directed mutagenesis primers for pCAGGS plasmids .................................................. 50 
Table 2. Oligomers used for sequence analysis of introduced mutation PB2A221T and PAD529N in pCAGG plasmids .. 50 
Table 3. Primer sequences used for quantification of gene expression in infected cells and viral mRNA transcription  ... 52 
Table 4. Antibodies used for Western blot detection of proteins during viral infection ................................................... 54 
Table 5. Antibodies used for cell suspension staining ....................................................................................................... 56 
Table 6. Evaluation of pathogenicity of recombinant viruses in mice.. ............................................................................ 63 
Table 7. Animals infected with CAL-PA recombinant virus experiencing sudden death early in infection.. ...................... 68 
Table 8. Inflammation process in infected mice lungs . .................................................................................................... 75 
 
Figures 
Figure 1. Seasonal and pandemic viruses.. ....................................................................................................................... 18 
Figure 2.  Structure of H1N1 viral particle ........................................................................................................................ 21 
Figure 3. Transcription and replication of viral segments during the infection. ............................................................... 24 
Figure 4. Influenza A virus polymerase. ............................................................................................................................ 26 
Figure 5. Defective genome (DG) accumulation during replication. ................................................................................. 29 
Figure 6. Possible mechanism of generation of defective genomes during viral replication process. .............................. 30 
Figure 7. Virulence and pathogenicity of F clinical isolate and defective genomes produced during influenza virus 
infection. ........................................................................................................................................................................... 32 
Figure 8. Antiviral cellular response. ................................................................................................................................. 34 
Figure 9. Model of detection of defective and full length gene segments during in vivo and in vitro infection.. ............. 52 
Figure 10. Growth kinetics of recombinant viruses in human alveolar cells. .................................................................... 61 
Figure 11. Relative polymerase activity of wild-type or mutant reconstituted RNPs........................................................ 62 
Figure 12.  Pathogenicity of recombinant viruses in in vivo infections ............................................................................ 64 
Figure 13. Pathogenicity of recombinant viruses in in vivo infections .............................................................................. 65 
Figure 14. In vivo analysis of recombinant virus infection ................................................................................................ 66 
Figure 15. Weight of superior and post-caval lung lobes ................................................................................................. 67 
Figure 16. Viral titer in the lungs of infected mice. ........................................................................................................... 67 
Figure 17. Kidneys weight of the mice infected with the different recombinant viruses .................................................. 69 
Figure 18. Hearts weight of the mice infected with the different recombinant viruses. ................................................... 69 
Figure 19. Recombinant viruses are able to infect heart tissue. ....................................................................................... 70 
Figure 20. Viral titer in heart samples of animals infected with the different recombinant viruses. ................................ 71 
Figure 21. Recombinant viruses are able to replicate in heart tissue of infected animals ................................................ 72 
Figure 22. Neutrophils. ..................................................................................................................................................... 73 
Figure 23. Alveolar macrophages ..................................................................................................................................... 73 
Figure 24. Dendritic Cells .................................................................................................................................................. 74 
Figure 25. Monocytes ....................................................................................................................................................... 75 
 
 
8 
 
Figure 26. Accumulation of antiviral proteins MxA and ISG56 and viral NP protein ........................................................ 76 
Figure 27. Relative amount of the indicated mRNAs in A549 cells infected at moi 0.5 with the different recombinant 
viruses. .............................................................................................................................................................................. 77 
Figure 28. Defective genomes in purified viral particles of recombinant viruses. ............................................................. 79 
Figure 29. Distribution of generated DGs per viral segment of recombinant viruses ....................................................... 80 
Figure 30. Detection of DGs and internal fragments from full length PB2 and PA genome segments in virions isolated 
from lungs of infected animals. ........................................................................................................................................ 81 
Figure 31. Production of DGs in recombinant viruses carrying mutations in the M and the PA segments....................... 81 
Figure 32. Distribution of generated DGs per viral segment of Cal-M and CAL-M/PA recombinant viruses. ................... 82 
Figure 33. Pathogenicity of CAL-M and CAL-M/PA in vivo. ............................................................................................... 82 
Figure 34. PA-C and PB1 catalytic domain in tetrameric state of polymerase complex.  ................................................. 90 
Figure 35. Defective genomes accumulation. ................................................................................................................... 93 
Figure 36. Representative electrocardiogram of control or flu infected animals.. ........................................................... 98 
 
 
  
 
 
9 
 
 
  
 
 
10 
 
 
  
 
 
11 
 
Summary 
Influenza virus is responsible for seasonal outbreaks that result in more than 5 million hospitalization and 500 000 
deaths every year. Analysis of two clinical AH1N1pdm09 pandemic isolates originated from a patient with mild (M 
strain) illness and a patient that deceased (F strain) from influenza related complication during the 2009 pandemic, 
highlighted three amino-acid changes PB2 A221T, PA D529N and HA S127L in the F isolate, that might be responsible 
for the increased virulence of this strain in vitro and in vivo. Furthermore, F isolate was able to accumulate less 
defective genomes (DGs) than M virus during the infection in cell culture as well as in animal model. Mutations found 
in F strain and their effects in F virus pathogenicity were studied by introducing its changes in A/California/04/09 (CAL) 
virus backbone. Although these mutations did not affect viral growth or polymerase activity in vitro, we found that 
PB2 A221T and HA S127L attenuated while PA D529N increased the already described pathogenicity of CAL virus in 
vivo. Besides 100 fold decreased LD50 , CAL-PA D529N virus showed high replication rates in lungs of infected animals 
and strong innate immune response cell influx (neutrophils, dendritic cells, monocytes, alveolar macrophages) and 
inflammation in early infection (2 day post-infection). Furthermore, CAL-PA D529N virus showed great potential of 
viral spread to extra-pulmonary organs. Animals infected with CAL-PA D529N virus  had infectious viral particles in 
heart tissue for a prolonged period of time (up to 4 days of infection) and at higher frequency (80% of animals) than 
CAL infected animals. We demonstrated that beside high viral titre, viral mRNAs of NEP, only present in cells with 
ongoing infection, were present in heart tissue of animals infected with CAL- PA D529N virus. Analysis of 
electrocardiogram (ECG) monitorization of infected animals showed that those infected with CAL-PA D529N virus 
suffered from systolic bradycardia and conduct cardiac defects. Accordingly with the data we obtained from studying 
F strain, CAL-PA D529N virus have low accumulation of defective genomes in cell culture as well as low induction of 
antiviral genes (MxA, ISG56). Additionally, our work shows that PA D529N mutation is able to reduce the accumulation 
of DGs in viruses with high DG accumulation capacity.  
In summary, PA D529N is responsible for increased pathogenicity of F strain. As a consequence of this mutation virus 
accumulates less DGs which partially delays timely antiviral response. This would allow virus to remain undetected by 
the infected cells for a relatively short but sufficient time period to enable viral replication. High replication rates in 
lungs of CAL-PA D529N virus and efficient viral spread into extra-pulmonary organs in animals increase its 
pathogenicity potential. These findings give us an insight into complex pathogenesis of influenza A viruses infections 
and the different ways it can affect final outcome of disease.  
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Resumen 
El virus de la gripe es responsable de brotes estacionales que suponen más de 5 millones de hospitalizaciones y 500 
000 muertos cada año. El análisis de dos aislados clínicos de la pandemia del 2009 (AH1N1pdm09), uno aislado de un 
paciente con síntomas leves (M) y otro de un paciente fallecido (F), puso de manifiesto la presencia de tres cambios de 
amino acido en el asilado F (PB2 A221T, PA D529N, HA S127L), que podrían ser los responsables de la virulencia 
exacerbada de este aislado. Además el aislado F presentó menor acumulación de genomas defectivos (DGs), que el 
aislado M tanto en viriones aislados de células en cultivo como de pulmones de ratones infectados. El papel de las 
mutaciones encontradas en el aislado F como posibles responsables de su patogenicidad, fue estudiado mediante la 
introducción de estos cambios en virus recombinantes de la cepa pandémica de referencia A/California/04/09 (CAL). 
Ninguna de las mutaciones afectaron la cinética de crecimiento o la actividad de la polimerasa viral in vitro, pero PB2 
A221T y HA S127L atenuaron y PA D529N incrementó la patogenicidad del virus CAL en el modelo de ratón. El virus 
recombinante CAL-PA D529N redujo 100 veces la LD50 de los ratones infectados, mostró alta tasa de replicación en 
los pulmones, potente reclutamiento de células de respuesta inmune innata (neutrófilos, células dendríticas, 
monocitos, macrófagos alveolares) e inflamación a tiempo temprano de infección (2 días post-infección). Además, el 
virus CAL-PA D529N mostró un gran potencial de infección en tejidos extrapulmonares, así los ratones infectados con 
este virus presentaron partículas infectivas en los corazones durante más tiempo (hasta 4 días post-infección) y a 
mayor frecuencia (80% de los animales infectados) que los ratones infectados con el virus CAL. La presencia de 
partículas infectivas en los corazones, fue el resultado de replicación viral en este órgano, ya que se detectó en ellos la 
presencia del mRNA de la proteína NEP, que únicamente es detectada como consecuencia de replicación. La 
monitorización del electrocardiograma de los ratones infectados con el virus CAL-PA D529N mostró la presencia de 
bradicardia sistólica y defectos en la conductancia. Similarmente al aislado F, el virus CAL-PA D529N acumuló una baja 
cantidad de DGs en los viriones aislados de células infectadas y de acuerdo con ello una baja inducción de genes 
antivirales (MxA, ISG56). Adicionalmente, observamos que la mutación PA D529N reduce la producción de DGs en 
virus con alta tasa de acumulación de estos genomas defectivos. 
En conclusión el cambio PA D529N es el responsable de la patogenicidad del aislado F. El virus recombinante 
conteniendo este cambio, acumula una baja cantidad de DGs, lo que retrasa la respuesta antiviral. Este hecho 
permitiría al virus permanecer indetectable por la célula infectada por un tiempo relativamente corto pero suficiente 
para permitir la replicación viral. Altas tasas de replicación en pulmón en los ratones infectados con CAL-PA D529N y 
una eficiente dispersión a tejidos extrapulmonares incrementarían su potencial de patogenicidad. Estos resultados nos 
aportan datos sobre el complejo mecanismo de patogenicidad del virus de la gripe y las diferentes vías que 
intervienen en el resultado final de la infección. 
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1. Influenza virus and flu 
 
Acute respiratory infections continue to be the main cause of acute illnesses worldwide and influenza A virus is one of 
the major contributors. Influenza virus is responsible for seasonal outbreaks that result in more than 5 million 
hospitalization and 500 000 deaths every year. Just during the last century it caused several pandemic outbreaks with 
severe public health and economic impact (WHO). 
Influenza virus belongs to the Orthomixoviridae family that consists out of 6 genera influenza A, B, C,  (Infectious 
salmon anemia), Thogoto virus and newly described D influenza viruses (Hause, Collin et al. 2014). Influenza A and B 
viruses co-circulate in human population and are responsible for the influenza, an acute respiratory disease infection 
of both upper and lower respiratory tract causing seasonal epidemics. Influenza type C infections cause mild 
respiratory illness and are not thought to cause epidemics. Usual symptoms of influenza infection are tracheitis and 
marked myalgia as well as fever which last up to 5 days (Couch 1996). 
Besides pulmonary complication, patients with severe flu infection show various cardiac dysfunctions. Myocarditis and 
pericarditis are well-recognized cardiac problems that may lead to heart impairment and cause high mortality by 
influenza virus infection (Mamas, Fraser et al. 2008). It has been reported the infection of both left and right ventricles 
in heart muscle of one patient who underwent cardiac arrest in very early stage of infection (3
rd
 day of infection) 
indicating that ability of viral strain to infect and induce inflammation in heart tissue greatly increase its pathogenicity 
(Komai, Nakazawa et al. 2011). Recent studies suggest that almost 10% of patients suffer from some cardiac 
abnormalities during the infection (Jeyanathan, Overgaard et al. 2013). All this implies that, influenza A virus H1N1 
may induce cardiac abnormalities which may have serious consequences on patients recovery. 
Renal complications followed by influenza A virus (IAV) infection are very rare and found in critically ill patients. These 
dysfunctions include acute kidney injury, rhabdomyolysis, hemolytic uremic syndrome etc. that can be followed by 
secondary bacterial kidney infection and affect patients overall medical condition. Disseminated intravascular 
coagulation and acute tubular necrosis were observed in fatal pandemic 2009 H1N1 (AH1N1pdm09) cases (Watanabe 
2013). 
Infection with A(H1N1)pdm09 strains caused rare but very serious neurological complications, especially in children. 
Complications include febrile seizures (epilepsy, nonketotic hyperglycinemia, anoxic encephalopathy), encephalitis 
etc. (Frobert, Sarret et al. 2011).  
In summary, viral spread of influenza H1N1 virus plays a key role in pathogenicity of particular virus. Ability of clinical 
strains to spread and infect non-target tissues causes severe and serious medical conditions and health disorders. 
Critically ill patients showed broad spectrum of medical complications that greatly impact their clinical picture and 
recovery.  
Seasonal epidemics are caused by both influenza A and B subtypes which are distinguished by two viral glycoproteins 
(hemagglutinin-HA, neuraminidase-NA). This is due to highly variable superficial viral glycoproteins (HA, NA) that allow 
them to escape the recognition by host virus specific antibodies. Gradual accumulation of changes in these proteins 
that retain a degree of serologic relationship with the currently prevailing strain, are called antigenic drift (Figure 1a). 
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Introduction of novel subtype with antigenically distinct superficial molecules showing no serologic relationship with 
strains circulating at the time is known as antigenic shift (Figure 1b). These late changes have been observed only in 
type A virus since it remains inside its reservoirs in various animals besides humans (pigs, horses, birds and other 
mammals). Efficient transmission from human to human of these antigenically distinct strains cause pandemic 
outbreaks since neutralizing antibodies to new reassortant virus are absent in the human population. 
 
Type B and C influenza viruses are almost exclusively restricted to humans as a host, therefore influenza A virus is the 
perfect candidate of possible introduction of a new viral subtype in the human population (Neumann, Noda et al. 
2009) with viral antigen to which most humans have no immune memory to (Neumann and Kawaoka 2006). In IAV, 18 
antigenically distinct HA and 11 NA proteins have been described so far. All possible combinations between them 
define the different subtypes of IAV. Once a new influenza subtype is introduced in human population, it may lead to 
human to human transmission that would cause pandemics, and occasionally serious infection outbreaks with severe 
illness and high mortality rate. Accordingly, there have been three major H1N1 influenza pandemics outbreaks in the 
twentieth century, and recently in 2009 the first pandemic of the 21
st
 century. 
The pandemic of 1918-1920 “Spanish” flu was the most devastating of all of them. Although the severity of infection 
led to death in 20-50 million people it is believed that this number is underestimated since there is a limitation of 
data, non-registration, misdiagnosis etc. (Johnson and Mueller 2002). “Spanish” flu pandemic showed an unusual 
mortality pattern with high mortality rates in healthy young adults (age 15 to 34) and children. Genetic 
characterization of this virus several decades later showed that it belongs to H1N1 influenza A subtype (Taubenberger, 
Figure 1. Seasonal and pandemic viruses. (a) Antigenic drift, responsible for seasonal epidemic, is a subtle change in viral 
glycoproteins (HA, NA) in an already circulating influenza subtype which preserves the same immune response. (b) Antigenic shift, 
responsible for pandemic outbreaks, consists on the introduction of completely new, segments usually from avian influenza 
subtype originating viruses with new glycoprotein into circulating human influenza subtype. This leads to appearance of new 
influenza subtype to which humans have no immunological memory to. 
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Reid et al. 1997) which along with secondary bacterial infection (Walters, D'Agnillo et al. 2016) caused high mortality. 
Studies have shown that viral replication complex, nonstructural protein 1 (NS1) and surface protein hemagglutinin 
(HA) contributed to its virulence (Neumann, Noda et al. 2009). Reconstituted 1918 influenza virus showed high 
virulence and mortality in murine model, embryonated chicken eggs (Tumpey, Basler et al. 2005) and macaque model 
(primate) as well as deregulated antiviral response that caused insufficient immune response that led to fatal outcome 
(Kobasa, Jones et al. 2007).  
The H1N1 IAV that appeared in 1918 circulated and caused occasional season epidemics in human population and pigs 
(Logan and Mac 1951) until its complete disappearance in 1957 when it was replaced with new human/avian 
reassortant H2N2 and H3N2 viruses (Scholtissek, Rohde et al. 1978). The “Asian” flu emerged in Southern China in 
1957. During 1957 and 1958, human/avian reassortant H2N2 virus caused excessed mortality worldwide causing 
almost 70 000 casualties in USA only (CDC). A new reassortant H3N2 (“Hong Kong” flu) emerged in July 1968 and 
replaced the H2N2 virus. Unlike the previous pandemics, severe illness and high mortality rates were observed in the 
elderly (above 65 years of age) with 33 800 registered deaths in 1968-1970 in USA. “Hong Kong” flu therefore is 
considered to be the mildest pandemic of the 20
th
 century (CDC).  
An H1N1 virus re-emerged again in 1977, “Russian” influenza, and resembled to that circulating in the 1950s 
(Nakajima, Desselberger et al. 1978). Both H1N1 and H3N2 viruses have been co-circulating in human population to 
this date occasionally generating novel hybrid H1N2 viruses (Guo, Xu et al. 1992). The most recent pandemic was 
originated in spring of 2009 when a new swine-origin H1N1 influenza A virus capable of human to human transmission 
emerged in USA and Mexico (CDC 2009-2010 ). Genetic studies of this new A(H1N1)pdm09 virus showed that it is a 
triple reassortant derived from North American H3N2, swine H1N1 and Eurasian “avian-like” swine H1N1 viruses 
(Girard, Tam et al. 2010).   
The actual number of cases worldwide during 2009 pandemic remains unknown. It has been estimated that about 60 
million people had been infected with A(H1N1)pdm09 only in USA (Bautista, Chotpitayasunondh et al. 2010). The 
most affected was younger population, children under 4 years of age and adults 18-64 of age. Unlike seasonal 
influenza, a high portion of hospitalization and deaths due to AH1N1pdm09 infection occurred in non-elderly adults 
(Presanis, De Angelis et al. 2009). With only 18500 laboratory confirmed deaths it has been estimated that pandemic 
H1N1 2009 produced between 151700 to 575400 fatalities due to both respiratory and cardiovascular complications, 
80% of them in adults under 65 years of age and 51% occurred in Southeast Asia and Africa (Dawood, Iuliano et al. 
2012).  
In addition to occasional pandemics, other influenza virus subtypes (swine, avian) can be transmitted from animals to 
humans (avian A/H5N1 in 1997, Hong Kong) causing severe infection. Furthermore, H5 and H7 subtypes constitute 
highly pathogenic avian influenza viruses (HPAIV), with mortality rate in humans of almost 100% (Alexander 2007). An 
effective human to human transmission of these highly pathogenic viruses poses a constant concern about the 
possibility of future human pandemic (de Jong, Claas et al. 1997). HPAIV H5N1 “bird” flu spread in birds causing severe 
outbreaks in poultry from Southern China to all East Asia, Central Asia, Europe and Africa during 2004-2006. This virus 
caused occasional viral infections to humans who were in direct contact with infected animals. Although, unable for 
human to human transmission, H5N1 virus caused severe illness with high mortality rates in humans. Avian A/H7N7 
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strain which appeared in Netherlands in 2003, with 450 infected people showed no human to human transmission but 
increased pathogenicity than seasonal strains (Koopmans, Wilbrink et al. 2004). Sometimes human to human 
transmittable reassortant strains do not show increased pathogenicity such was 1999 avian A/H9N2 which appeared 
in Hong Kong displaying mild symptoms in patients, but showed some genome similarity to highly pathogenic H5N1 
isolates few years before (Lin, Shaw et al. 2000). Therefore, human to human transmittable and highly pathogenic 
reassortant strain is a rare phenomenon having into account the huge potential of influenza virus to evolve and adapt 
to new host. However, it does present a constant threat and risk to public health, since avian subtypes (H5N1, H7N7 
and H9N2), to which humans are completely immunologically naïve, circulate in domestic and wild poultry and can be 
easily introduced in human population causing serious infections with severe illness and threatening medical 
conditions. More recently in 2013 avian origin H7N9 virus infected several persons in Shanghai, China with high 
mortality rate and rapid lower respiratory tract infection. Complications included respiratory distress syndrome and 
multi-organ failure (Gao, Cao et al. 2013).   
All these outbreaks present a constant threat to human health and great economic challenge especially in the less 
developed countries where monitoring of existing influenza reservoirs in both domestic and wild poultry is not 
sufficient or adequate. Therefore, a detailed insight into pathways by which these viruses evolve and become lethal is 
the key to develop more effective prevention and protection strategies against highly pathogenic and transmittable 
influenza strains.  
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2. Structure of influenza A virus 
 
Since the first isolation of infectious particles in both pigs (Shope 1931) and human (Wilson Smith 1933) in the early 
1930s, numerous studies have revealed the structure of influenza A viral particle. It possesses a segmented negative 
single stranded RNA (ssRNA) genome. Influenza A virus genome is formed out of 8 ssRNAs that encode 16 proteins, 
including a new one detected very recently (Yamayoshi, Watanabe et al. 2015).  
 
 
The surface of the viral particle contains a lipid membrane originated from the cellular membrane of infected host 
cell. Two glycoproteins, the hemagglutinin (HA) and the neuraminidase (NA) together with the matrix protein 2 (M2) 
embedded in the surface of the viral particle, are the primary target for neutralizing antibodies during the infection. 
There are 18 antigenically distinct HA and 11 NA proteins described so far. All possible combinations between them 
define the different subtypes of influenza A virus. Some aquatic wild birds (ducks, geese, swans etc.) are the natural 
reservoirs of all characterized subtypes of influenza virus. In bats only, H17N10 (Tong, Li et al. 2012) and H18N11 
(Tong, Zhu et al. 2013) subtypes have been described. Matrix protein 1 (M1) forms an inner layer of viral particle, and 
interacts with both M2 on the outer side and NEP on the inner side of the particle. In the nucleus of viral particle, 8 
viral ribonucleoproteins (vRNPs) can be observed (Figure 2). vRNPs are formed out of (-) ssRNA, completely coated 
with nucleoprotein (NP) and with viral polymerase bound to a double-helix RNA structure formed by the 5’ and the 3’ 
complementary ends of (-)ssRNA.  
Viral RNA dependent RNA (vRdR) polymerase is formed out of 3 subunits: polymerase basic 1 (PB1), polymerase basic 
2 (PB2) and polymerase acidic (PA) subunits. More detailed description of viral polymerase will be discussed latter on. 
 
Figure 2.  Structure of H1N1 viral particle. Viral envelope is consisted of hemagglutinin (HA), neuraminidase (NA) and matrix 
protein 2 (M2) situated in the lipid membrane positioned just above protein capsid formed by the matrix protein 1 (M1), which 
interacts with M2 on the outer, and nuclear export protein (NEP) on the inner side of particle. Nucleus of viral particle contains 8 
viral ribonucleoproteins (vRNPs). 
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2.1 Hemagglutinin HA 
 
Hemagglutinin (HA) represents the primary mediator of viral entry. It is a trimer that has two structurally distinct 
regions (stalk and globular regions) (Wilson, Skehel et al. 1981). Viral entry depends on two independent 
conformational changes in the HA molecule. The first includes cleavage of HA precursor structure into HA1 and HA2. 
This allows the formation of a fusion competent structure that can bind to HA receptors on the cell surface and initiate 
viral entry. After the internalization of viral particle there is a second conformational change, a relocation of the N-
terminal domain of the HA2 subunit. This change is induced by a lower pH in the cell endosome. Fusion peptide 
domain, which is highly conserved in influenza A and B viruses, is relocated to interact with the endosomal membrane 
and is the crucial part of the fusion process (Skehel and Wiley 2000, Steinhauer 2010). HA glycoprotein attaches to the 
glycan sialic acid-containing receptors on the surface of the cell membrane. Sialic acid (SA), a derivative of neuraminic 
acid, is present in the termini of oligosaccharides attached to glycoproteins and glycolipids on the cell surface. 
Infectivity of influenza virus is influenced by sialic acid species (N-acetylneuraminic and N-glycolylneuramic acid) and 
the type of linkage (α2,6 or α2,3) to galactose (Gal) on the glycan oligosaccharides. Hemagglutinin of human influenza 
A virus recognizes SA α2,6 Gal (Rogers and Paulson 1983), which is the linkage found in the epithelial cells of the 
human upper respiratory tract (Couceiro, Paulson et al. 1993). Linkage of HA to SA α2,3 was found on the epithelial 
cells of duck intestine and it has been shown that avian viruses preferentially bind  to these receptors, while pig 
trachea epithelia contains both types of SA and both types of linkages, which makes them a unique “mixing vessel” for 
generation of new reassortant viruses (Ito, Couceiro et al. 1998). It has been documented that despite the difference 
in the specificity of the receptors, viruses originated from other species (avian, swine) have infected humans causing 
lethal infections (pandemics, local epidemics) due to SA α2,3 receptors on the ciliated cells of human respiratory tract 
(Matrosovich, Matrosovich et al. 2004, Ibricevic, Pekosz et al. 2006). Although avian viruses can potentially infect 
humans with efficient human to human transmission they have to overcome receptor specificity, since they 
preferentially recognize SA α2,3 receptors. The ability of some avian strains to recognize SA α2,6 receptors provides 
efficient replication in the human upper respiratory tract and it also aids in transmission via droplets, which was the 
case in previous pandemics (Matrosovich, Tuzikov et al. 2000, Gamblin, Haire et al. 2004).  
The structure of HA protein has been the target of many studies since its change of affinity from SA α2,3 to SA α2,6 
linkage may be a critical step in generating pandemic influenza strains. Over 30 years ago it has been demonstrated 
that difference in just one amino acid changes affinity of HA from avian to human receptors (Rogers, Paulson et al. 
1983). Nowadays, several of these changes have been described and identified as key factors determining the host 
specificity binding to HA receptors. Mutations Q226L and variable position 228 in human H2 and H3 strains increase 
their affinity to SA α2,6 receptor, as well as E190D, and variable position 137 and G225E in human H1 strains 
(Matrosovich, Tuzikov et al. 2000, Ni, Kondrashkina et al. 2015). Avian HA that has both 226L/228G or 226L/228S in 
HA, preferentially binds to SA α2,6 receptors in the upper respiratory tract of ferrets, efficiently replicates and induces 
high levels of neutralizing antibodies compared to the strain with the 226Q/228G residues (Chen, Zhou et al. 2012).  
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2.2 Neuraminidase NA  
 
NA gene encodes neuraminidase (NA), one of the surface proteins of influenza A virus particles (Figure 2). NA 
possesses sialidase enzyme activity, which allows the removal of sialic acid from the cell membrane liberating viral 
particles from cells. Similarly to HA, the neuraminidase needs to adapt to human host receptor, containing SA α2,6 
linkage in order to prevent self-aggregation and obtain efficient replication. NA is a tetramer that is formed out of a 
box-shaped head and a slender stalk (Varghese, Laver et al. 1983). The length of the stalk affects host range of 
influenza A virus and the longer the stalk is, the more efficient replication is in cells culture, eggs (Zhang, Xue et al. 
2011) and murine model (Castrucci and Kawaoka 1993).  
2.3 Matrix proteins  
 
M segment encodes two proteins, matrix protein 1 (M1) and matrix protein 2 (M2). M1 derives from the translation of 
the collinear transcript of M segment and M2 derives from the spliced form of the M segment transcript. An 
alternative spliced form of this segment which encodes M3 peptide has been described (Shih, Nemeroff et al. 1995) 
but its function seems to be unessential for viral growth in cell culture (Jackson and Lamb 2008). Another alternative 
spliced form of M segment, mRNA4 encodes an M2-related protein, M42 (Wise, Hutchinson et al. 2012). M1 protein is 
a dimer and forms matrix protein capsid based just beneath the lipid envelope. 
M1 interacts with viral ribonucleoproteins on the inner side of the particle, and with HA, NA and M2 proteins on the 
surface, and also establishes interactions with nuclear export protein (NEP) (Yasuda, Nakada et al. 1993) (Figure 2). 
This makes it a unique bridge between envelope and core of the viral particle (Nayak, Hui et al. 2004) with a major 
role in budding and formation of newly synthesized virions (Gomez-Puertas, Albo et al. 2000), and in the nuclear 
transport of the vRNPs in infected cell (Martin and Helenius 1991).  
M2 membrane protein has three different domains: extracellular domain that is a target for the host immune 
response (Lamb, Zebedee et al. 1985), transmembrane domain that has ion channel activity and is involved in 
uncoating of viral particles (Pinto, Holsinger et al. 1992) and intracellular domain that interacts with M1 protein 
(Zebedee and Lamb 1989).  Since M1 and M2 proteins are involved in various processes during viral infection, M 
segment is much conserved in influenza A strains. This makes the M segment host specific; one of many factors that 
determinate host range of influenza A viruses. The M2 has a stronger selective pressure than M1 in both human and 
swine strains since it is a major antigen marker (Furuse, Suzuki et al. 2009).   
2.4 Nucleoprotein NP 
  
Nucleoprotein (NP) is a constituent of viral ribonucleoproteins vRNPs. Viral RNA segments are coated with strings of 
NP protein. Each NP binds viral RNA at every 24 nt in order to form ribonucleoprotein complexes (vRNPs) (Ortega, 
Martin-Benito et al. 2000). RNPs complexes are located inside the particle core and can be described as double-helical 
RNP structures (Ye 2010). NP is multifunctional protein important in various viral processes: intracellular viral genome 
trafficking, replication, packing and assembly of virions. It is phylogenetically conserved among influenza A strains. 
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This protein has head and body domains with an RNA binding domain in the groove between these two domains 
(Coloma, Valpuesta et al. 2009).  
2.5 Non-structural 1 (NS1) and nuclear export (NEP) proteins  
 
NS1 derives from the translation of the collinear transcript of NS segment while NEP derives from the spliced form of 
the NS segment transcript. An alternative spliced form of this segment which encodes NS3 peptide which seems to 
positively affect viral growth has been described (Selman, Dankar et al. 2012). NS1 is a small protein with a major 
function in counteracting the host antiviral response and constitutes one of the main virulence factors of influenza 
virus. It is composed of two functional domains the N-terminal RNA binding domain and the C-terminal effector 
domain.  This multifunctional dimeric protein binds to dsRNA in infected cells before they are detected by the cellular 
dsRNA viral receptors. By doing so, it inhibits the activation of cellular antiviral response and delays the IFN-mediated 
response (Garcia-Sastre, Egorov et al. 1998). 
NEP is a very small protein that has a key role in the nuclear export trafficking of vRNPs (Iwatsuki-Horimoto, Horimoto 
et al. 2004). NEP enters the nucleus of the infected cells by passive transport but its export depends on active 
transport trough CMP-1. Viral strains of influenza A virus with deficient NEP have a delayed nuclear export of vRNPs 
which result in decreased viral growth in both cell culture and mice (Iwatsuki-Horimoto, Horimoto et al. 2004).  
2.6 Viral RNA dependent RNA polymerase (vRdRP)  
 
Infection and spreading of virus mostly depend on two crucial processes, transcription and replication of viral genome. 
Both of these processes take place in the nucleus of the infected cell. Viral RNA dependent RNA polymerase (vRdRP) 
has a central role in the life cycle of influenza A virus. Viral polymerase is a heterotrimeric complex formed by three 
subunits; polymerase basic 1 (PB1), polymerase basic 2 (PB2) and polymerase acidic (PA). 
  
Figure 3. Transcription and replication of viral segments during the infection. Viral RNA is transcribed (a) to mRNA with CAP 
structure at 5’end and replicated (b) to complementary RNA (cRNA) by polymerase, which then serves as a template for 
accumulation of viral genome 
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All vRNA segments possess 3’ and 5’ highly conserved ends that have partial complementary sequences which form a 
doble-helix vRNA panhandle structure. Polymerase complex binds to the promoter situated at the panhandle 
structure on each viral segment (Fodor, Pritlove et al. 1994) and its recognition by the viral polymerase is crucial for 
initiation of both transcription (vRNA to mRNA) and replication (vRNA to cRNA as well as cRNA to vRNA) of the viral 
genome (Figure 3). PB1 polymerase subunit contains the conserved motifs that form the polymerase active site (Poch, 
Sauvaget et al. 1989). Transcription begins with a cap-snatching process in which methylated cap structure of host 
pre-mRNA 5’ end is first recognized and bound by the PB2 subunit (Guilligay, Tarendeau et al. 2008) and then cleaved 
by a PA subunit endonuclease activity, 10-13 nucleotides away from the cap structure (Dias, Bouvier et al. 2009). This 
snatched cap–oligo is then used as a primer for the viral mRNA synthesis (Figure 3a). Recent reports show that the 
‘cap-snatching’ process requires substantial conformational reorganization of the complex, especially PB2 subunit 
(Reich, Guilligay et al. 2014). Viral mRNAs possess a poly A tail at 3’ end generated by the stuttering mechanism of the 
polymerase complex (Reich, Guilligay et al. 2014).  
Replication proceeds in a primer-independent manner (Figure 3b). Viral RNA replication involves the synthesis of cap-
independent, full-length positive-stranded RNAs complementary to the genomic vRNAs, named cRNAs, which serve as 
a template for the amplification of new vRNAs. Both vRNAs and cRNAs are coated by NP forming cRNPs and vRNPs, 
respectively. A recent study suggests that replication may be initiated by binding of the 5’ hook to a pocket of the PB1 
and PA interaction (Pflug, Guilligay et al. 2014).  The mechanism by which polymerase is able to switch from one 
process to another is yet to be fully described.  
3. Polymerase subunits and pathogenicity of virus 
 
Pathogenicity is a multifactorial property of every influenza A viral strain. It depends on the nature of the virus itself, 
the immune response of the host and its capacity to overthrow the infection in a complex interplay of both factors. 
Changes in genome allow virus to adapt to new conditions and viral polymerase has a key role in the process of 
generation of new mutations in every viral gene. Besides frequent changes of the surface proteins (HA, NA), which 
enable infection, adaptive mutations are found in every viral gene responsible for modulation of host antiviral 
response or efficient replication and growth of virus in the host. Influenza A virus polymerase generates one 
spontaneous mutation per replicated genome (Drake 1993). Without proofreading activity the viral polymerase is 
capable of producing 10
4
 mutated viruses in just one infected cell (Boivin, Cusack et al. 2010). This feature of 
polymerase gives a huge variability of viral genome in just one replication cycle. It permits a virus to evolve very soon, 
very fast and obtain resistance basically to all therapeutic tools used so far.  
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3.1 Polymerase basic 2 subunit PB2 
 
Protein polymerase basic 2 subunit (PB2) is transcribed from the longest viral segment. N-terminus of PB2 protein 
interacts with C terminus of PB1 in the polymerase complex (Sugiyama, Obayashi et al. 2009). This protein has a 5’-
cap structure binding activity (Figure 4) that is used for binding to host pre-mRNAs, a crucial step for viral transcription 
(Poole, Medcalf et al. 2007). PB2 protein plays an important role in the pathogenicity of influenza virus. It contains a 
host range determinant at position 627 since only one amino acid change (E→K) at this position in PB2 allows the 
growth of an avian virus in mammals. Most avian strains have a glutamic acid at this position, while almost all human 
strains possess a lysine (Subbarao, London et al. 1993). Avian H5N1 strains containing a lysine at this position have 
increased pathogenicity and infectivity in mice (Hatta, Gao et al. 2001). This leads to the conclusion that 627K in PB2 is 
a pathogenicity marker in mammalian species.  The temperature on which different origin strains are replicated 
provides a possible explanation for this phenotype. Human strains replicate in upper respiratory tract at 33˚C while 
avian in intestine at 41˚C. Avian 627E strains in PB2 show thermosensitive phenotype with low efficiency of replication 
at lower temperature, while human 627K strains had the same rate of replication (Massin, van der Werf et al. 2001).  
Another amino acid has been characterized as host range determinant involved in adaptation of H5N1 strain to mice 
(Li, Chen et al. 2005). Adaptive change D→N in PB2 protein at position 701 is responsible for the enhanced binding to 
nuclear transporter importin α1 in mammalian cells while it does not affect PB2 nuclear transport in avian cells 
(Gabriel, Herwig et al. 2008). The 701 change can be accompanied by another nearby, S→R, change at position 714, 
which has been found in the avian strains highly pathogenic for mammalian species. This mutation promotes the 
Figure 4. Influenza A virus polymerase. Viral polymerase complex presented in two different views (a) and (b) with vRNA promotor 
(pink and yellow) following the color code presented in figure (d) showing the subdomains of every polymerase subunit; (c) 
monomeric structure of viral polymerase and its subunits in space filling side-view representation (10.1038/nature14008) 
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phenotype described by 701 change; accumulation of importin α in nucleus of infected cell and enhanced nuclear 
transport of PB2 polymerase subunits (Czudai-Matwich, Otte et al. 2014). The 588 change (T→I) found in the 
pandemic 2009 strain (A(H1N1)pdm09) showed to be an adaptive change to mammalian cell replication and increased 
virulence and mortality in mice (Zhao, Yi et al. 2014). PB2 588 (T→I) proteins have lower binding affinity for 
mitochondrial antiviral signaling proteins (MAVS) and therefore inhibit induction of interferon type I antiviral response 
(Zhao, Yi et al. 2014).   
Recently, an alternative splicing product of PB2 segment has been detected in infected cells with several H1N1 strains. 
Similar donor-acceptor splice sites were found in all H1N1 strains prior to A(H1N1)pdm09; however H3N2 and 
pandemics H1N1 strains do not possess these sequences (Yamayoshi, Watanabe et al. 2015). Protein encoded by this 
spliced RNA, PB2-S1 protein, localizes with mitochondria and inhibits RIG-I pathway thus alters antiviral response in 
infected cells (Yamayoshi, Watanabe et al. 2015). 
Another important domain of PB2 protein is its mitochondrial antiviral signaling proteins (MAVS) binding domain. 
Unlike avian strains, PB2 of human influenza strains co-localizes with MAVS and induces lower levels of antiviral 
response mediated by interferon β (IFN-β) in cell culture while viral growth is not affected (Graef, Vreede et al. 2010). 
These strains are attenuated in murine model. It has been shown that N→D change at position 9 in avian strains is 
responsible for acquiring functional MAVS binding domain (Graef, Vreede et al. 2010). Swine origin 2009 pandemic 
strains do not possess this change in PB2 protein (Graef, Vreede et al. 2010).  
3.2 Polymerase basic 1 subunit PB1 
 
PB1 segment encodes two proteins, polymerase basic 1 (PB1) and PB1-F2 protein which is the product of a +1 
displacement in the reading frame. PB1 protein interacts both with PB2 and PA subunits of the viral polymerase and 
contains the polymerase active site, with sequence motifs characteristic of viral RNA-dependent RNA polymerases 
which are essential for its activity (Figure 4).  A N375S change has been found in all pandemic strains before 2009. 
Interestingly, although human strains almost uniformly possess serine, avian strains show much more diversity having 
serine, asparagine and threonine at this position (Taubenberger, Reid et al. 2005).  
PB1-F2 is recognized by the CD8+T lymphocytes (Chen, Calvo et al. 2001) and exposure of monocytes to PB1-F2 led to 
induced apoptosis and cell death (Chen, Calvo et al. 2001). In the absence of PB1-F2, PB1 has altered location, which 
affects polymerase activity, indicating that interaction between PB1 and PB1-F2 regulates the polymerase activity 
(Mazur, Anhlan et al. 2008). Changes in this protein lead to higher pathogenicity and lethality in mice model while 
delaying the adequate innate immune response (Conenello, Zamarin et al. 2007).  PB1-F2 was not present in 
A(H1N1)pdm09 virus. 
3.3 Polymerase acidic subunit PA 
 
Polymerase acidic (PA) and PA-X are proteins transcribed from the PA viral segment. PA contains two domains: N-
terminal (1-256 aa) and C-terminal (257-716 aa) separated by a peptide linker (Maier, Kashiwagi et al. 2008). The C 
terminal domain is responsible for the interaction with N-terminal of PB1 polymerase subunit (Obayashi, Yoshida et al. 
 
 
28 
 
2008). Aside from stabilizing the polymerase complex, PA subunit is involved in proteolysis of both viral and host 
proteins (Sanz-Ezquerro, Zurcher et al. 1996, Rodriguez, Perez-Gonzalez et al. 2007). Cristal structure of PA subunit 
gave us a detailed insight into both, the C and N-terminal domains (Figure 4), demonstrating that N-terminal domain 
contains an endonuclease putative active site motif P107D108X10E119K134 involved in the cap-snatching process of viral 
transcription (Yuan, Bartlam et al. 2009). Several changes in the PA protein have been described as host range 
determinants. For instance, 2009 pandemic strains have an avian PA subunit with various adaptive changes to 
mammalian host such are at 85(T→I), 186(G→S) and 336(L→M) positions that enhance viral growth in cell culture. The 
T85I change provides high titers in human alveolar epithelial cells A549 while L336M change increases viral 
pathogenicity in mice model (Bussey, Desmet et al. 2011).  
PA-X is produced through a ribosomal frameshifting and contains the endonuclease domain of the PA polymerase 
subunit followed by a new sequence of 61 aa translated from a different reading frame. It is involved in various 
processes in the viral infection by modulating the host innate antiviral response (Jagger, Wise et al. 2012). PA-X 
induces cellular shut off in the cell culture more efficiently than PA N-terminal fragments (Desmet, Bussey et al. 2013).  
Sequence of PA-X is variable and often trunked in H3N2 and H3N8 strains, which might be associated with host 
specific adaptation of the virus (Shi, Jagger et al. 2012). PA-X was not detected in any A(H1N1)pdm09 strain. 
4.  Generation of defective genomes (DGs) 
 
Generation of defective viruses is a unique feature of some RNA viruses (dengue virus, Sendai, hepatitis, influenza…). 
In the early 50s, it was observed accumulation of defective and non-infectious viruses in serial passages of influenza 
viruses at high multiplicity of infections in embryonated chicken eggs (Von Magnus 1954). Defective interfering RNAs 
(DIs) were detected and named later when the suitable technics for their detection were available. They possess the 3’ 
and 5’ ends of the parental RNA segments and most have large, single, central deletion (Figure 5). They are capable of 
interfering with viral replication by competing with the initial full-length viral genes in vitro (Huang 1973). These 
incomplete genome RNAs may not always interfere with viral replication if they are not accumulated at high 
concentration compared to complete RNA genome, but other attributes of this short RNAs have been described. 
Therefore, the correct form to name them is defective genomes or DGs (further text).  Since their accumulation may 
disturb replication and consequently viral spread, the ratio between generated DGs and full-length RNA segments may 
determine the final outcome of infection. 
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High production of DGs would, at one point, work as a limiting factor for viral propagation. It has been described that 
the majority of DGs detected in influenza virus is originated from polymerase segments PB2, PB1 and PA (Dimmock 
and Easton 2014). Most DGs are 180-1000 nt long (Davis and Nayak 1979, Noble and Dimmock 1995), and have about 
20% of original length in average (400 nt) (Dimmock and Easton 2014).  
Defective particles are unable to replicate without the presence of infective particles with complete segment 
information (Nayak 1980). The mechanism of production of DGs is still unclear and even though tremendous efforts to 
study this process have been employed in the past few decades, generation of defective genomes in influenza virus 
infections remains an unknown process (Figure 5 and 6). DGs are also generated in vivo; sequence analysis of 
nasopharyngeal samples from patients infected with A(H1N1)pdm09 strains showed similar distribution of DGs, 
generated principally from polymerase genes with similar length found in in vitro samples. Interestingly enough, 
patients that had been in direct contact shared the same DGs (Saira, Lin et al. 2013).   
Figure 5. Defective genome (DG) accumulation during replication. (a) Viral segments during the process of replication loss a 
large central fragments which ends in accumulation of deleted products (b), small RNAs with identical 3’ vRNA and 5’ vRNA ends 
and incomplete viral genome information (DGs). 
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All experiments with DGs particles are not fully reproducible. Naturally generated stocks possess mix of DGs with 
different interference capability and its content is not stable throughout passages. Cloned viruses that have single 
main type of DG RNA provide a protection in secondary influenza virus infection in both mice (Dimmock, Rainsford et 
al. 2008) and ferrets (Dimmock, Dove et al. 2012), giving the possibility of using DGs as a tool against influenza 
infections.  
4.1 Effects of DGs during the infection 
 
Mammalian cells have developed various strategies in order to detect antigens of different pathogens. Pathogen 
recognition receptors (PRRs) recognize antigens and activate the cellular response in infected cell. Antiviral response 
of infected cells depends on the adequate and quick recognition of viral antigens by cells’ PRRs.  It has been observed 
that short dsRNA or ssRNA activate antiviral response predominantly by binding to one of cytoplasmic PRRs that 
recognizes these molecules with high affinity (RIG-I). Induction of this antiviral pattern leads to induction of type I 
interferon response (Kell and Gale 2015). Detailed antiviral response will be the subject of the next chapter.  
Truncated forms of viral genome (DG) can, besides the already described interference in replication of viral genome, 
induce the antiviral response in infected cells. Defective genomes have been detected in various plant and mammalian 
cell cultures and also in patients with acute and chronic hepatitis A (Nuesch, de Chastonay et al. 1989), B (Rosmorduc, 
Petit et al. 1995) and C (Noppornpanth, Smits et al. 2007) infection, HIV infections (Inoue, Hoxie et al. 1991), Dengue 
virus (Li, Lott et al. 2011) and influenza virus (Saira, Lin et al. 2013) infections. Copy-back defective genome in Sendai 
Figure 6. Possible mechanism of generation of defective genomes during viral replication process. (a) Viral polymerase complex 
(PB1, PB2 and PA) starts replication of viral genome (red) by removing the nucleoprotein (NP) from vRNPs, in 5’-3’ sense producing 
complementary (+) sense RNA stains (blue). During this process viral polymerase may flip from 3’-end side and proceeds replication 
of 5’-end side of  viral genome (b), producing (+) strain, cRNA, which possess complementary 3’ and 5’ends of (-) viral genome and 
large central deletion. (c)  Replication of this short, cRNA into viral genome, vRNA (red) leads to progressive accumulation of viral 
genome with uncomplete genome information, defective genome (DG). Other alternative of DGs production may occur during the 
replication process from cRNA to vRNA.  
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virus in in vitro infection induces cytokine response and maturation of mouse and human dendritic cells, which may 
provoke earlier induction of adaptive immune response (Mercado-Lopez, Cotter et al. 2013).  Sendai virus with high 
loads of defective genomes promotes expression of interferon stimulated genes (ISGs), independently of TLR or type I 
interferon pathway (Yount, Gitlin et al. 2008).  In in vivo infection with the same virus it has been shown induction of 
IFN-β and IL-6 in the lungs of infected mice (Tapia, Kim et al. 2013). Furthermore, infection of human lung slices with 
respiratory syncytial virus (RSV) with high DGs content provokes a vigorous antiviral response dominated by IFN-λ1 
and IFN-β stimuli (Sun, Jain et al. 2015).  Similar results were observed in influenza A virus infected mice. Antiviral 
response in animals infected with a virus generating large amount of DGs, induced high expression of IFN-β, with 
reduced morbidity rate of mice infected with influenza A H1N1 virus (Tapia, Kim et al. 2013).  Therefore, in both in 
vivo and in vitro infections, antiviral response with DG enriched viruses is stronger than in infections with viruses with 
low DG content independently of viral origin or mechanism of DG generation.  
Infection of mice without activated adaptive immune system showed that DGs are able to protect animals in the early 
stage of infection but the clearance of infection was obstructed and delayed (Scott, Meng et al. 2011). Innate immune 
response against viruses which accumulate low amount of DGs is not enough to protect from developing a severe 
illness. Therefore, adaptive immune response needs to be activated by already DG-induced active innate response in 
order to obtain full protection (Scott, Meng et al. 2011). DGs rich viruses can both enhance maturation of dendritic 
cells as well as the adaptive immune response (Yount, Kraus et al. 2006). DGs have a universal potential to induce 
antiviral response in infected cells and therefore have a significant impact on the progress of infection and illness.   
Accumulation of defective genomes in influenza A infection depends on the multiplicity of infection but also on the 
nature of viral strain itself. Changes in viral polymerase subunits may be responsible for DGs production ability in 
different viral strains. Thus, fidelity and processivity of viral polymerase has crucial effect on overall DGs production in 
influenza virus infection.  
DGs upon cell entry can be transcribed into functional mRNA that can be translated into polypeptides (Akkina, 
Chambers et al. 1984). Newly detected protein, encoded from the mRNA derived from a PB2 segment DG of H5N1 
virus, alters IFN type I response in cell culture independently of the RIG-I pathway, the usual antiviral response 
inducted by DGs (Boergeling, Rozhdestvensky et al. 2015). Unlike PB2 protein, DG mRNA product, PB2∆, induces the 
production of IFN-β and IFN-β stimulated genes and lowers the viral titer of influenza A virus in vitro by binding to a 
MAVS on the mitochondrial membrane. In mice model, the strain with PB2∆ expressed protein showed increased 
pathogenicity in vivo and enhanced cytokine response (Boergeling, Rozhdestvensky et al. 2015). This opens a 
completely new perspective on the DGs and their expression in influenza A viruses infection.  
After years and years of investigation it seems that, even though DGs are considered a byproduct of replication, there 
are many questions to be responded regarding their generation and functions. Other byproducts of replication, 
numerous mutations in viral genome, together contribute to viral pathogenicity and adaptation to mammalian cells. 
Different evolution strategies, where the error prone activity of viral polymerase is involved, affect humans and could 
be responsible for developing a severe illness and a fatal outcome. 
 
 
 
32 
 
5. Characterization of DGs production in isolates of influenza A viruses from 2009 pandemic 
 
Despite all described data related to DGs in cell culture and animal models, the possible correlation of DGs and 
pathogenicity in influenza infected patients have never been evaluated. 
In order to evaluate whether influenza strains with increased virulence may coexist among circulating viruses previous 
studies in our laboratory characterized two IAV strains from  AH1N1 2009 pandemic (A(H1N1)pdm09), one isolated 
from a fatal case in a person with no known comorbidities (F) and the other from a patient with mild symptoms (M) 
(Rodriguez, Falcon et al. 2013). This study showed that F virus replicates faster in cell culture and has increased 
pathogenicity in animal model causing significant more weight loss and mortality of animals compared to M strain 
(Rodriguez, Falcon et al. 2013)(Figure 7).  
 
Deep-sequencing of viral genome of these strains showed that there are 9 amino-acid changes between F and M 
strains in PB2, PA, NP, HA and NA gene segments. Sequence comparison with a consensus amino acid sequence 
obtained using the influenza virus resource database from NCBI and including around one thousand 2009 pandemic 
viruses isolated in the time frame of one month before and after the isolation date of M and F viruses, highlighted 
three amino-acid changes PB2 A221T, PA D529N and HA S127L in the F isolate (Rodriguez, Falcon et al. 2013), that 
might be responsible for the increased virulence of F strain. In addition to the consensus viral genome, the deep 
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Figure 7. Virulence and pathogenicity of F clinical isolate and defective genomes produced during influenza virus infection. (a) 
Growth kinetic of M and F viruses in human alveolar A549 cell line infected at moi 10
-3
pfu/cell. Viral yield was determined by 
plaque assay in the MDCK cells. (b) Mice were intranasally inoculated with 10
6
 PFU (50 µl) of either M or F influenza viruses or 
were mock infected with 50 µl of PBS and were monitored daily for survival for 14 days. (c) DG ratios, calculated as jumping reads 
per million (RPM) that align the viral genome, determined in purified virions from the fatal (F) or the mild case (M) of IAV 
infection 
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sequence of RNA isolated from F and M virions showed the presence of defective genome (DGs) in both samples, but 
an almost 10-fold lower DGs amount was observed in the F than in the M virus (Figure 7).  
6. Antiviral response in infected cells 
 
In order to infect, the virus must first enter through nasal or oral cavities. After reaching respiratory tract, viral 
particles must penetrate a mucus layer that covers respiratory epithelia. Only then, virus is able to bind to 
pneumocytes and non-target immune cells in the respiratory tract. These cells represent the first active barrier against 
the virus.  As mentioned before, mammalian cells have co-evolved, along with viruses, in order to quickly and 
efficiently recognize and neutralize viral antigens. Pathogen associated molecular patterns PAMPs, viral antigens, are 
recognized by cellular PRRs that are represented by distinct classes: Toll-like receptors (TLRs), retinoic-acid inducible 
gene I-like receptors (RLRs), NOD-like receptor family member, NOD-LRR-and pyrin domain-containing 3 (NLRP3) and 
C-type lectin receptors (CLPs). These receptors have a different location in the cell and represent unique guardians 
with a mission to eradicate infection and to alert neighboring cells and circulating specific immune cells. RLRs and TLRs 
are the most characterized PRRs involved in antiviral response upon influenza virus infection.  
6.1 Recognition of PAMPs. First cascade of antiviral response 
6.1.1 RLRs. Retinoic-acid inducible gene I - RIG-I 
 
RLRs include RIG-I, melanoma differentiation associated factor 5 (MDA5) and LGP2 protein, which belong to the 
DExD/H box RNA helicases family (Loo and Gale 2011). In the cytosol of the infected cell RLRs recognize 5’-
trisphosphate RNAs and dsRNA which triggers a type I interferon (IFN) antiviral response (Hornung, Ellegast et al. 
2006). Besides 5’-trisphosphate another feature of viral RNA is necessary for RIG-I recognition, the 3’-polyU motifs of 
viral genome (Saito, Owen et al. 2008). Through this mechanism RIG-I specifically recognizes non-self, viral RNA, 
avoiding the recognition of cellular RNAs (Saito, Owen et al. 2008). Long dsRNA fragments are primary target of MDA5 
while RIG-I shows preference to short dsRNA PAMPs (Kato, Takeuchi et al. 2008). More in detail, viral RNA is 
recognized by RIG-I helicase domain, while at the same time RIG-I caspase recruiting domains (CARD-like domains) 
(Yoneyama, Kikuchi et al. 2004) are subjected to conformational change by which these domains become exposed and 
can interact with tripartite motif protein (TRIM25) that binds to one of these domains and subsequently ubiquitinates 
the other CARD domain (Gack, Shin et al. 2007, Gack, Kirchhofer et al. 2008). This facilitates CARD-CARD interaction to 
interferon-β promoter stimulatory 1 protein (IPS-1) also known as MAVS, VISA or Cardif. This last factor activates 
phosphorylation of interferon regulatory factor 3 (IRF3), IRF7 and NF-κβ and subsequently induces IFN type-I synthesis 
(Kawai, Takahashi et al. 2005, Meylan, Curran et al. 2005). A diagram of these pathways is presented further on 
(Figure 8a). 
 
 
 
34 
 
 
Influenza virus has adapted and evolved several mechanisms to overcome the induced antiviral cell response. One of 
which is trough non-structural viral protein 1 (NS1) which is capable to repress induction of IFN type I response by 
inhibiting antiviral RIG-I pathway (Garcia-Sastre, Egorov et al. 1998). NS1 binds to TRIM25 proteins and disable 
ubiquitination of RIG-I CARD and downstream signalization of IFN type I response (Gack, Albrecht et al. 2009).   
6.1.2 Toll-like receptors - TLRs  
 
Toll-like receptors are the best characterized family of all PRR members. TLRs are transmembrane proteins expressed 
on the cell surface and intracellular vesicles membrane with PAMPs recognition ability and are formed out of three 
domains: leucine reach repeats ectodomain, transmembrane domain, and cytosolic Toll-IL-1 receptor (TIR). During 
viral infections crucial TLR members sense nuclear acids; TLR3 recognizes dsRNA, TLR7 and TLR8 recognize ssRNA and 
TLR9, which target unmethylated CpG motifs of dsDNA. TLR2 and TLR4 can detect viral antigens but are specific for 
certain viruses (Kawai and Akira 2011).  
Most of the TLRs (among which TLR7, TLR8) are associated with MyD88 adapter and upon detection of infection, 
MyD88 dimerizes. This dimerization induces a signal cascade in infected cell that leads to  activation of TANK binding 
Figure 8. Antiviral cellular response. (a) Recognition of viral RNA by PRRs induces signal cascade which triggers synthesis of 
cytokines and IFN α and β. IFNAR receptors (IFN-α/β) on the neighboring uninfected cells (b) induces another signal cascade that 
ends with activation of transcription of many antiviral genes (MxA, ISG56…) 
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kinase 1 (TBK1) and inducible IκB kinase that activates IRF3 that along with IRF7 induce transcription of type I IFN in 
the infected cell (Figure 8a) (Sharma, tenOever et al. 2003, Hacker, Redecke et al. 2006). 
TLR3 receptor is associated with other adaptor molecule, TRIF, through its TIR domain. Activated TRIF associates with 
TRAF6 and TBK1 pathway (Sato, Sugiyama et al. 2003) that activates IRF3 (Fitzgerald, McWhirter et al. 2003)  but also 
receptor interacting proteins, RIP1 and RIP3, where RIP1 is responsible for activation of  NF-κβ (Meylan, Burns et al. 
2004). Therefore, since localization of different TLRs in virus infected cell is diverse they show different functions. TLR3 
as a surface cell protein is able to detect nearby infected cells and prompts antiviral state of the uninfected cell. TLR7 
and TLR8 based on the intracellular vesicles sense infection inside the cell and induce antiviral response (Iwasaki and 
Pillai 2014).  
6.2 Activation of antiviral genes. Second cascade of antiviral response 
 
Although, RLRs and TLRs activate different signal pathways, both induce the same cell antiviral response mediated by 
production of interferon type I, α and β (IFN-α, IFN-β). Secreted IFN acts both autocrine and paracrine and binds to the 
IFN-α/β receptor (IFNAR) expressed on the surface of the cells (Figure 8b). Binding of IFN to its receptor activates a 
cascade that starts with phosphorylation of tyrosine kinase 1 (Jak1) and 2 (Tyk2), following the phosphorylation of 
STAT1 and STAT2 that work as signal transducers and activators of transcription. STAT1 and STAT2 then associate with 
IRF9 forming an interferon stimulated gene factor 3 transcription complex (ISGF3) which is translocated to the nucleus 
where induces transcription of antiviral genes (ISGs) (Goodbourn, Didcock et al. 2000). ISGs possess ISRE elements that 
are target sequence for ISGF3. Some of these genes encode antiviral proteins that affect viral production in the 
infected cells. Protein kinase R (PKR), 2’-5’ olygoadenylate synthetase (OAS), Myxovirus resistance gene A (MxA), and 
IFN induced transmembrane proteins (IFITMs) are some of the proteins with antiviral effect transcribed by IFN 
induction.   
6.2.1 ISGs 
 
- Protein kinase R (PKR) upon sensing dsRNA, dimerizes and suffers autophosphorylation which leads to 
phosphorylation of eukaryotic initiation factor 2α-subunit (eIF2α) and subsequent inhibition of translation in  the host 
cell (Pham, Santa Maria et al. 2016).   
- 2’-5’ olygoadenylate synthetase (OAS) detects dsRNA and activate RNase L which promotes RNA degradation 
(Kristiansen, Gad et al. 2011) and enhanced RIG-I mediated antiviral response (Zhu, Zhang et al. 2014). 
- MxA and its mouse ortholog the Mx1 protein, belong to a dynamin superfamily of large GTPase (Haller and Kochs 
2011). MxA is a cytosolic protein (Ciancanelli, Abel et al. 2016), that inhibits nuclear transport of influenza virus NP, 
which affects influenza virus transcription and replication (Kochs and Haller 1999). In almost all inbred mice strains 
Mx1 is defective and with this in mind should be analyzed all data regarding antiviral response produced in infected 
animals (Cilloniz, Pantin-Jackwood et al. 2012).  
- Interferon inducible transmembrane proteins (IFITMs) block viral entry but they do not show the same antiviral 
pattern in all viral infections. In influenza A infections IFITM3 (ISG60) response is more conspicuous than IFITM1 
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(ISG56) and IFTM2 (ISG54) (Bailey, Zhong et al. 2014). IFITM3 is expressed in the target cells of IAV in respiratory tract, 
as well as in macrophages and has a fundamental role controlling influenza A virus in vivo (Bailey, Huang et al. 2012).  
Regardless of the pathway all these processes lead to the same aim, activation of antiviral, local, response and 
synthesis of type I IFN, pro-inflammatory cytokines and chemokines that are responsible for activation of innate 
immune response and immune cell recruitment which would subsequently lead to induction of inflammation process 
and viral clearance in infected tissue.  Adequate host response to viral inflammation is a crucial feature in progression 
of illness and patient recovery process. Therefore, host antiviral and inflammation response to viral infection 
contribute to pathogenicity of viral strain.   
7. Innate immune response upon influenza virus infection 
 
Adequate and timely response to the influenza infection is a crucial factor in disease development and final outcome. 
Immune system possesses three levels of protection of pathogens, first is the physical barriers (skin, mucosae…), the 
second corresponds to the innate (natural) response effective 4-96 hours of infection and the third is the adaptive 
(acquired) response detectable after 96 hours upon the infection. Innate immune response is a non-specific and non-
selective response largely dependent on the leukocyte activation, while adaptive immune response is unique and 
selective and therefore starts only when needed. Leukocytes detect PAMPs through PRRs (TLRs and NOD) and prompt 
virus clearance by induction of phagocytosis, a target cell lysis and inflammation process mediated by increased 
secretion of pro-inflammatory cytokines: interleukins (IL-1,6, 8, 12, 18), tumor necrosis factor-TNF, and IFN-α/β. 
Myeloid (granulocytes, monocytes, macrophages and dendritic cells-DC), lymphoid (T and B lymphocytes, NK, NKT 
cells and DC) and mast linage cell members are involved in different stages of immune response(Mak, Jett et al. 2011).  
Type II alveolar cells and alveolar macrophages are primary targets of influenza A virus and strong inducers of IFN 
mediated antiviral response. Besides antiviral proteins, infected type II alveolar cells secrete  various pro-inflammatory 
cytokines (interleukins, IL-8 which recruits neutrophils, macrophages and mast cells (Deshmane, Kremlev et al. 2009) 
and  IL-6 and chemokines (MCP-1 which recruits monocytes and macrophages, RANTES, and MIP-1β) whereas alveolar 
macrophages produce tumor necrosis factor α, TNF-α (Deshmane, Kremlev et al. 2009, Wang, Oberley-Deegan et al. 
2009). Macrophage inflammatory protein MIP-1α promotes pro-inflammatory process in cells but also inhibits 
proliferation of hematopoietic stem cells and has an important role controlling inflammation in influenza infection 
(Cook 1996). The synthesis of antiviral factors that takes place during IAV infection provokes significant influx of innate 
immune response cells that are almost immediately involved in the virus clearance and de novo recruitment and 
activation of adaptive immune response. 
7.1 Neutrophils 
 
In inflammatory process neutrophils are the first leukocytes that target the infection focus. After detection of PAMPs, 
activated neutrophils immediately phagocyte the pathogens and by fuse them with phagosome scavenge the source 
of inflammation.  Neutrophils also release the phagosome content to the extracellular matrix, which in acute and 
persistent inflammation can damage adjacent healthy tissue and cause acute pulmonary distress syndrome (APDS) 
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(Martin, Pistorese et al. 1991). Other granulocyte leukocytes, basophils and eosinophils also induce phagocytosis upon 
detection of infection but are represented in a smaller number in the blood than neutrophils (Mak, Jett et al. 2011). 
Neutrophil influx in influenza infected respiratory tissue is essential for recruitment of CD8
+
T cells (Lim, Hyun et al. 
2015). Recent studies show that human neutrophils, even though they do not possess sialic acid could be infected 
with AH1N1pdm09 virus. Apart from entry, virus is able to replicate inside these cells and spread. It is hypothesized 
that these leukocytes may represent an advantage for virus spread outside the target tissue (Zhang, Huang et al. 
2015). Lethality by influenza A virus in the mice model has been correlated with tissue damage caused by inadequate, 
vigorous neutrophil influx and subsequently induced inflammation (Brandes, Klauschen et al. 2013).  
7.2 Monocytes 
 
Monocytes are the prevalent cells circulating in the blood and represent 3-5% of all leukocytes. Differentiation of 
phagocytes to macrophages occurs in the inflamed tissue. Monocytes can also differentiate into myeloid dendritic 
cells (mDCs) in some physiological conditions like infections. These mDCs do not express pro-inflammatory cytokines, 
but chemoattractants (MCP-1, IP10), type I IFNs and thus ISGs (Cao, Taylor et al. 2012).  
7.3 Macrophages 
 
Macrophages are large, long live phagocytes that patrol and reside in all organs and tissues constantly engulfing 
damaged host cells and cell debris as well as the pathogens. Differentiation in a particular microenvironment in their 
resident tissue cause subtle differences in morphology and function (alveolar macrophages (AM) in lung, Kupffer cells 
in liver, osteoclast in bones). Upon activation by external material (cellular debris, spent host cells, foreign entities, 
pathogens…) macrophages induce phagocytosis and secretion of cytokines, growth factors and chemokines alerting 
others leukocytes (neutrophils, T and B lymphocytes) (Mak, Jett et al. 2011). AMs have an important role in viral 
clearance and affect virus induced morbidity. Influenza H1N1 infected mice with defected, immature AM show high 
morbidity and mortality despite functional and efficient adaptive response, which mark these cells as the key factor of 
immune protection from influenza infection (Schneider, Nobs et al. 2014).  
7.4 Dendritic cells 
 
Dendritic cells (DCs) can be differentiated from both myeloid and lymphoid precursor and give numerous subtypes 
with subtle differences in the immune response. Along with macrophages, DCs represent professional antigen 
presenting cells (APC). Maturation of DCs occurs when these cells encounter pathogen which induces production of 
cytokines and activation of T adaptive response (Mak, Jett et al. 2011). Using macaques as animal model, it has been 
reported that highly pathogenic H5N1 strains efficiently infect and induce apoptosis of mature DCs in both infected 
lung and draining nodes in the early infection, altering the synthesis of type I IFN and activation of adequate adaptive 
response (Baskin, Bielefeldt-Ohmann et al. 2009).  
Therefore, pathogenicity and virulence of any viral strain depend on a complex interplay of both viral and host factors. 
Viral entry, replication, activation of antiviral response in infected cell, innate immune response and ability to spread 
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beyond viral primary target cells greatly affect the illnesses progress and final outcome of the disease. The aim of this 
thesis is to analyse all these factors together in order to understand what makes an influenza virus lethal.   
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The main objective of this thesis is the identification and characterization of the pathogenic determinants responsible 
for the lethal phenotype of a viral strain isolated from a fatal case. The putative virulence determinants observed in 
this viral strain (PB2 A221T; PA D529N and HA S127L) have not been previously associated with pathogenicity in A or B 
influenza viruses and their characterization may provide very valuable information to reveal which viral factors make 
an influenza virus lethal. 
 
Objetives  
 
1. To study the contribution of exclusive changes found in the F viral strain to their virulence in vitro 
 
 
2. To evaluate the contribution of putative pathogenic factors of the F viral strain to the viral pathogenesis in 
the murine model for influenza virus infection. 
 
 
3. To characterize virus spread potential to non-respiratory organs in in vivo infection with viruses carrying 
mutations found in the F strain 
 
 
4. To investigate defective genome production of the F virus and viruses bearing exclusive changes found in F in 
vitro and to evaluate their contribution to viral pathogenicity in vivo. 
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Materials and Methods 
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I Materials 
1. Cell lines 
 
Madin-Darby canine kidney (MDCK) cells, 293T human embriotic kidney (HEK293T) cells, and human type II alveolar 
epithelial (A549) cells obtained from American Type Culture Collection (ATCC) were maintained in Dulbecco’s minimal 
essential medium (DMEM; GIBCO) with 1% of non-essential amino acids (INVITROGEN) and 10% fetal bovine serum 
(FBS; LINUS ) inactivated by incubation at 50˚C for 30 minutes. Propagation of cell lines was performed by serial 
passages every 3-4 days in order to avoid confluence.  Cells were washed with 1x PBS (GIBCO) before every passage 
and then treated with 0.25% trypsin (SIGMA T4665) and 0.02% EDTA; in case of HEK293T cell line trypsin/EDTA mix 
was diluted 10 times. Cells were cultivated at 37˚C at atmosphere with 5% CO2 and 98% humidity. 
For experimental purposes, cell passages were done a day before the experiments and therefore recently grown cells 
were used for every in vitro study. Cell wash was performed with complete 1xPBS before any treatment (transfection, 
infection etc.). 
2. Viral strains 
 
Human viral isolates – H1N1 viruses used in this study were obtained from the Spanish National Influenza Centre 
during 2009 pandemic. Viruses were isolated from bronchealveolar lavages of one fatal influenza virus infected 
patient (F) and one patient who showed mild influenza symptoms (M) (Rodriguez, Falcon et al. 2013). 
Recombinant viruses –Recombinant influenza viruses bearing rare mutations detected in F strain and absent in M 
strain; HA S127L (CAL-HA), PB2 A221T (CAL-PB2), PA D529N mutations (CAL-PA), the combination of these polymerase 
changes (CAL-PB2/PA; F virus-like polymerase) or all possible combinations were generated on the A/California/04/09 
(CAL) virus backbone. 
Recombinant CAL viruses carrying mutations in M segment (M1 86S/M2 30N) (Perez-Cidoncha, Killip et al.) alone (CAL-
M) or with mutated PA D529N (CAL-M-PA) were also generated.  
All recombinant viruses were generated in the lab by Ana Falcón or Noelia Zamarreño (manuscript under review) 
following the protocol previously described (Neumann, Watanabe et al. 1999, Falcon, Marion et al. 2004).  
Virus ΔNS1, corresponds to an influenza virus lacking NS1 protein (Garcia-Sastre, Egorov et al. 1998). This virus is 
unable to counteract the IFN response.  
3. Plasmids 
 
PCAGGs plasmids are derived from CAL/04/09 strain (courtesy of Dr. Y.Kawaoka) and carried wt PB2, PA and NP 
proteins or PB2 segment with A221T change and PA segment with D529N found in the F virus. 
PHH-NSCAT plasmid expresses the vRNA of cloramphenicol acetil transferase CAT in negative sense orientation under 
the Pol I promotor (Gonzalez and Ortin 1999). 
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4. Bacteria strains 
 
Ultracompetent XL10-Gold (STARTAGENE) with genotype Tet
r   
∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 
thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacI
q
ZDM15 Tn10 (Tet
r
) Amy Cam
r
] were used for transformation. 
5. Antibodies 
 
Antibodies used for Western Blot analysis 
PB1- anti viral PB1 polyclonal antibody obtained from immunized rabbit, used at 1:1000 dilution (Gonzalez and Ortin 
1999) 
NP- anti viral NP polyclonal antibody obtained from immunized rabbit, used at 1:5000 dilution (Jorba, Coloma et al. 
2009) 
ISG56 (IFIT1) – anti human ISG56 polyclonal antibody obtained from immunized goat used at 1:1000 dilution (IFIT1 (N-
16), SantaCruz, sc-82946) 
Mx 1/2/3 – anti human Mx1 polyclonal antibody obtained from immunized rabbit used at 1:1000 dilution, Mx 1/2/3 
(H-285)( SantaCruz, sc-50509) 
β-actin – anti human β-actin monoclonal antibody obtained from immunized mouse used at 1:2000 dilution (Sigma) 
GAPDH – anti human polyclonal antibody obtained from immunized rabbit used at 1:1000 (ABCAM, ab-9485) 
5.1 Antibodies used for flow cytometry analysis 
 
Monoclonal antibodies used for flow cytometry were obtained from several commercial houses conjugated with 
different molecules as presented in Table 5. 
6. Mice strains 
 
The animal strain used in these studies was female BALB/c AnNHsd mice (6-7 weeks old) obtained from Harlan, USA 
and maintained in the animal facilities of National Centre of Biotechnology (CNB-CSIC). 
7. Other material 
 
Hu IFN-α2a - Recombinant human interferon alpha A (PBL Assay Science, 11100-1) 
LB medium - Luria Bertani Broth (Sigma) 
RPMI-1640 medium (Invitrogen) 
Erythrocyte lysis buffer – 0.15M NH4Cl, 10mM NaHCO3, 0.1mM EDTA (Tritiplex), pH=7.4. 
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Disruption buffer – 64% 10M urea, 21% SDS (20%), 15% β-mercaptoetanol, bromophenol blue  
Transference buffer - 10% of 10X buffer ( Tris 250mMl, glicin 1.92M, SDS 1%), 20% methanol (Merck). 
Penicillin/Streptomycin – 100 IU/ml (Gibco, Thermofisher scientific, ref. 15140122) 
II Methods 
1. Viral manipulation 
1.1 Viral stock generation 
 
F, M and all recombinant viruses were collected in semi-confluent monolayer of MDCK cells when cytopathic effect 
was 75-100%. Primary obtained viruses (blind passage) were used in new infection at moi 10
-3
 for generation of 
secondary harvested viral stocks for further use. These 10
-3
 viral stocks were used in every experiment except for deep 
sequence analysis where stocks generated at moi 10
-5 
were analysed. 
1.2 Viral titter estimation 
 
Viral titters of both in vitro and in vivo samples were determined by standard plaque detection in MDCK cells. Briefly, 
approximately 6x10
5
 cells were infected with 100 µl of various serial dilution of viral samples in 5 μg/ml bovine serum 
albumin complete PBS (PBS-BSA) for 1h at 37˚C at atmosphere with 5% CO2 and 98% humidity. Upon infection and 
removal of inoculum, cells were incubated for 72 hours in semisolid DMEM, 0.4% agar, 1 % DEAE-dextran y 2.5 μg/ ml 
trypsin medium at 37˚C at atmosphere with 5% CO2 and 98% humidity. Viral titter was calculated by standard function 
by which number of plaques multiplied by factor of dilution of inoculum per ml.  
1.3 Purification of viral particles 
 
MDCK-infected cell culture supernatants were harvest at approximately 36-40 hours of infection and then centrifuged 
at 3110 g at 4°C for 10 min. Further on, supernatants were sedimented through a sucrose step gradient (TNE; 50% and 
33% in 50 mM Tris-HCl, 100 mM NaCl, 5 mM EDTA, pH 7.5) for 1 h at 27400 g at 4°C in a SW41 rotor. The 50 to 33% 
interphase was collected, diluted in TNE buffer, and pelleted through a cushion of 33% sucrose in TNE at 11200 g at 
4°C in a SW28 rotor for 2 h. For purification of viruses isolated from infected mouse lungs, the previous protocol was 
used with modifications of the sucrose gradient volume and rotors according to sample. 
2. Bacterial transformation 
 
Ultracompetent XL10-Gold (STARTAGENE) E.coli bacteria (50µl) were incubated for 30 min on ice and then 10µl of 
purified plasmid was added. Mix was incubated for the next 20 min at 4˚C, then 1 min at 42˚C and finally 5 min at 4˚C 
when 1ml of LB was added. Cells were incubated for 1h at 37 ˚C. After centrifugation at 8000rmp for 3 min at RT, 
200µl of supernatant was left with cell pellet, mixed gently and plated on the AmpLB agar plate (ampicillin 0.1mg/ml). 
Plates were incubated O/N at 37 ˚C. Bacteria colonies observed the next day were collected and grown in 5ml liquid 
AmpLB at 37 ˚C O/N. 
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3. DNA and RNA manipulation 
 3.1 Mutagenesis of pCAGGs-PB2 and PA plasmids derived from CAL/04/09 
 
Specific mutations were engineered in expression pCAGGS plasmids derived from the CAL strain using the 
QuickChangeTM site-directed mutagenesis kit (Stratagene) as recommended by the manufacturer. These materials 
were developed using the Licensed technology (Kawaoka-P99264US Recombinant Influenza viruses for vaccines and 
gene therapy). Primers used for site-directed mutagenesis of pCAGGS plasmids can be found in the table below (Table 
1). 
pCAGGs–mutPB2 and pCAGGs-mutPA were generated by PCR preheating the total mix 1 min at 95˚C and followed by 
35 rounds for 1min at 95˚C, 1min at 55˚C and 7 min of elongation at 65˚C. Amplified products were purified adding 
1%TNE, 36% of miliQ H20 and 50% of phenol, mixed and centrifuged at 12000rmp on 4˚C for 5 min. Pellet was washed 
with 2.5 volumes of 100% ethanol and 2µg of glycogen left for o/n precipitation at - 20˚C. Precipitate was then 
centrifuged at 12000rmp at 4˚C for 30 min and pellet washed twice with 70% ethanol and once with 100% ethanol, 
with short centrifugation of 5 min at 12000rmp at 4˚C between each wash. Dried pellet was re-suspended in miliQ 
H2O.  
After mutagenesis, the plasmids were transformed in bacteria as indicated above (Methods 2). Selected bacteria 
colonies were grown and plasmids were purified using QIAprep Spin Miniprep Kit (Quiagen) following the protocol 
recommended by manufacturer. To confirm the incorporation of point mutations,   pCAGG-PB2 and PA plasmids were 
sequenced as recommended by Macrogen, using both forward and reverse primers (Table 2).  
 
 
Table 2. Oligomers used for sequence analysis of introduced mutation PB2A221T and PAD529N in pCAGG plasmids 
Table 1. Sequence of specific site-directed mutagenesis primers for pCAGGS plasmids 
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3.2 RNA extraction 
3.2.1 Viral RNA 
 
For viral RNA isolation, viral stocks and purified virions were treated with 0.5% SDS and 200μg/ml proteinase K in TNE 
for 2h at 37ºC (Rodriguez, Falcon et al. 2013) followed by extraction with phenol-chloroform-isoamylalcohol-
hydroxyquinolein and ethanol precipitation. DNA was removed by treatment with DNAse I recombinant, RNase-free 
(Roche), following instructions of the manufacturer.  
3.2.2 Cellular RNA 
 
RNA isolation from cell cultures and animal tissues was performed with TRIzol (Invitrogen, 15596018)/chloroform 
(MERCK)) extraction according to manufacturer´s instructions. Samples collected with TRIzol reagent and 1/5 volume 
of chloroform were incubated at RT for 5 minutes and then centrifuged at 13000rmp at 4˚C for 20 min. Aqueous phase 
was collected and 1 volume of isopropanol was added. Samples were precipitated O/N at -20˚C. Precipitate was then 
centrifuged at 12000rmp for 30 min at 4ºC and pellet washed twice with 70% ethanol and once with 100% ethanol, 
with short centrifugation of 5 min at 12000rmp at 4˚C between each wash. Air dried pellet was re-suspended in RNase 
free H2O. DNA was removed by treatment with DNAse I recombinant, RNase-free (Roche), following instructions of 
the manufacturer. 
Quantity and quality analysis of RNA samples were performed by absorbance measuring at 260nm by NanoDrop ND-
1000. All RNA samples were stored at -80˚C.  
3.3 PCR  
3.3.1 Quantification of gene expression (qPCR) 
 
RNA samples obtained from various in vitro and in vivo samples were extracted as previously described (Methods 3.2). 
Reverse transcription of RNA samples was performed by High Capacity RNA Transcriptase Kit (Applied System, Thermo 
Fisher Scientific) following the manufacture recommendations, using random primers, provided within High Capacity 
RNA Transcriptase Kit (Applied System, Thermo Fisher Scientific) except for transcription of NEP viral gene where 
PolydT16 of TaqMan Reverse Transcriptase Reagans (Applied System, Thermo Fisher Scientific) were used as a primer.  
RNA samples used in these RT-PCR reactions were 100ng. PCR was performed in Applied Biosystems 2720 Thermal 
Cycler.  
For estimation of gene expression we used quantitative PCR approach. Previously isolated and transcribed RNA 
samples were quantify with this technique by Power SYBR green PCR master mix (Applied Biosystems, 4369679) 
following the manufacturer recommendations, using 10% of reverse transcribed cDNA, and 5% of 10mM primers from 
the table below (Table 3). For estimation of gene expression we used Thermocycler 7500 Real Time PCR Biosystems 2 
min at 50°, 10 min at 94° 40 cycling stages of 15s at 94° and 1min at 60°. As a standard curve plasmids with integrated 
fragments of ISG56 and MxA genes quantified by absorbance measured at 260nm by NanoDrop ND-1000 were used. 
In case of NEP mRNA detection, fragments were previously amplified from RNA sample of A549 infected cells then 
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quantified and used as standard curve. Human 28SrRNA and mouse β-actin were used as internal control in each 
sample; therefore they were not quantified but were used for normalization of data obtained. 
 
3.3.2 Detection of defective genome (DGs)  
 
For detection of DGs, 100 ng RNA samples extracted from purified viral particles (infected cells, infected mice lungs) or 
infected mice lungs were used for amplification using one step Titan One Tube RT-PCR Kit (Roche) applying all the 
manufacturer recommendations. RT-PCR for the PA and PB2 segments were used to determine the presence of DGs 
originated from these two segments.  To detect full-length (PA and PB2) segments, internal primers were used to 
amplify central fragments.  To detect DGs, same RNA sample and external primers of the PA and PB2 segments were 
used in a separate reaction. Short amplification time was applied for both external and internal primers (not provided 
due to intellectual properties issues). Model of detection of both full length and defective gene segments is shown in 
the Figure 9. 
Table 3. Primer sequences used for quantification of gene expression in infected cells and viral mRNA transcription 
Figure 9. Model of detection of defective and full length gene segments during in vivo and in vitro infection.  Central fragment 
(black) of the whole viral gene is amplified by specific internal primers (black arrows), defective genomes (dark red) with central 
deletion were amplified by a specific 3’ and 5’-end gene specific primers (dark red arrows) in two different RT-PCR reaction. 
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The reverse transcription reaction was performed for 30 min at 42°C and then PCR was performed for 35 rounds of 
94°C for 30 s, 59°C 30 s, and 68°C for 40 s for PB2 gene amplification, and 35 rounds of 94°C for 30 s, 53°C 30 s, and 
68°C for 40 s for PA gene amplification at Applied Biosystems 2720 Thermal Cycler. As a specificity control, the primers 
and RT-PCR conditions for DGs amplification were used with a plasmid encoding the full-length PA segment, and no 
amplification product was obtained. 
3.4 Deep sequencing  
 
Recombinant viruses were sequenced with TruSeq v3 chemistry and 50 bp single reads on an Illumina HiSeq 2000. 
3.4.1 Deep sequencing data analysis 
3.4.1.1 Short read alignment against the influenza genome 
 
For each sample, FASTQ sequences were aligned against the influenza (A/California/04/09) genome with TopHat2 
(Kim, Pertea et al. 2013), allowing intron size ranges between 5 and 10
5
 nucleotides. Samtools (Li, Handsaker et al. 
2009) was used to extract reads that aligned as two separate fragments (jumping reads) from the BAM files generated 
by TopHat2. Only reads split into two fragments that align at distant segment positions (jumping reads) and with both 
fragments of four or more nucleotides were selected. 
3.4.1.2 Viral sequence consensus determination 
 
To determine the consensus sequence of each virus, coverage and nucleotide composition of aligned reads were 
analysed. Nucleotide positions with an identity of ≥75% were considered. Samtools mpileup (Li, Handsaker et al. 2009) 
and in-house php scripts were used. 
3.4.1.3 Junction quantification, filtering and normalization 
 
Jumping reeds that aligned at least 4 out of 50 nucleotides, followed by ≥100 nucleotides gap and then aligned the 
rest of the sequence were considered defective genome junctions. Only defective segments generated by two or more 
jumping reads spanning exactly the same coordinates and that generate a theoretical final RNA segment size of ≤1000 
nucleotides were selected. For samples from the year 2009 (F and M virus), read orientation could not be determined 
as the sequencing protocol applied was not strand-specific. In the remaining samples, only reads from genomic RNA 
strand were counted. For each sample, values for jumping reads per million (RPM) were calculated as the sum of all 
selected jumping reads divided by the number of total reads that aligned with the influenza genome, then multiplied 
by 10
6
.  For analysis of jumping reads per segment, RPM values were normalized to total reads aligned with each RNA 
segment of the genome. 
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4. Protein accumulation analysis 
4.1. Enzyme-Linked ImmunoSorbent Assay (ELISA) 
 
For chloramphenicol acetyl transferase detection CAT ELISA (Roche, 11363727001) commercial kit was used following 
the manufacture recommendations. Accumulation of CAT enzyme was quantified by measuring absorbance at 405nm 
wavelength on microplate reader (EZ Read 400, Biochrom). 
4.2. Western blot 
 
Samples were collected in disruption buffer (Materials 7), sonicated (S3000-010 Misonix Incorporated, New York, USA) 
3 cycles for 10 s in water. After protein denaturation at 100˚C for 10 min, samples were centrifugated at 12000rmp at 
4˚C for 5 min. Proteins were separated by 8% SDS-PAGE gel electrophoresis (40 mA, 150V) and transferred to polivinil 
floured filters (PVDF membrane, Immobilon P Milipore) in transference buffer (Materials 7) O/N at 200mA at 4˚C in 
semi-liquid electrotransfering system (Biorad).   
For western blotting of viral proteins the membranes were saturated with 3% bovine serum albumin for 2 h and then 
incubated with the primary antibodies (diluted in PBS-0.05% Tween 20) for 1 h at room temperature. For Western 
blotting of human proteins, the membranes were saturated with TBS-5% milk for 2h at room temperature or o/n at 
4ºC and then incubated with the primary antibodies (diluted in TBS-0.05% Tween 20) overnight at 4°C. The filters were 
washed with PBS or TBS containing 0.25% Tween 20 and incubated with the appropriate secondary antibody 
conjugated to horseradish peroxidase. After further washing, the filters were developed by enhanced 
chemiluminescence by membrane incubation with solution (100mM Tris pH8.5, 250mM luminol, 90mM cumaric acid, 
1µl H2O2) for 1 min. Exposition of X-ray films sensible for chemiluminiscence to a PVDF membrane was between 1 s-10 
min, depending on experiment. Visualisation of the signal on the X-ray films with detected protein was performed by 
M-35 X-OMAT Processor (Kodak). List of antibodies used for Western Blot and conditions were described in the table 
below (Table 4). 
Table 4. Antibodies used for Western blot detection of proteins during viral infection 
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5.  In vivo studies 
5.1 Ethics statement  
 
All the procedures that required the use of animals complied with Spanish and European legislation concerning 
vivisection and the use of genetically modified organisms, and the protocols were approved by the National Centre for 
Biotechnology Ethics Committees on Animal Experimentation and the Consejo Superior de Investigaciones Científicas 
(CSIC) Bioethics Subcommittee. In particular, we follow the Guidelines included in the current Spanish legislation on 
protection for animals used in research and other scientific aims: RD 1201/2005, 10 October and the current European 
Union Directive 86/609/CEE, DOCE 12.12.86 (N.L358/1 to N.L358/28) on protection for animals used in 
experimentation and other scientific aims.   
5.2 In vivo infections 
 
All in vivo infections were performed on animal under anaesthesia, induced by exposition to vapours of  Isofluorane 
(ISOflo -Ecuphar) for a few minutes.    
To calculate lethal dose 50 (LD50), 4 female BALB/c AnNHsd mice (6-7 weeks old) were infected intranasally with 
several doses (10
2
-10
6
 pfu/50µl DMEM) of each of the recombinant influenza viruses described here, or were mock-
infected (50µl DMEM). The animals were monitored daily for clinical signs (piloerection, mobility and wellbeing) and 
body weights for two weeks.  For ethical reasons, mice were euthanized when they presented 25% body weight loss.  
For the kinetics experiment, 5 female BALB/c mice (6-7 weeks old) were infected intranasally with a sublethal dose 
(10
3
 pfu/50µl DMEM) of recombinant wild-type CAL, CAL-HA, CAL-PA, CAL-PB2 or CAL-PB2/PA influenza viruses, or 
were mock-infected (50µl DMEM). At 1, 2, 4 and 7 dpi, mice were euthanized by CO2 inhalation and necropsied.   
5.3 Organs extraction 
 
Left kidney, heart and lungs were surgically extracted from all sacrificed animals infected with sublethal viral doses at 
different time points of infection (1
st
, 2
nd
, 4
th
 and 7
th
 dpi). Heart and kidney samples were extracted as the whole 
organ and kept at -80˚C. Lung sample of each mice were divided in to 4 samples: superior and post-caval lobes were 
used for RNA analysis, kept at -80˚C, middle and inferior lobes for viral titer estimation, kept at -80˚C, while left lobe 
was used for histology analysis (lower left lobe) and flow cytometry analysis (upper left lobe). 
5.4 Viral titer estimation in extracted organs 
 
Tissue samples were homogenized (2x vol/weight) in PBS-0.3%-BSA-penicillin/streptomycin (100 IU/ml) using an 
Electronic Douncer (IKA T10 basic, Workcenter). Lung and heart samples were homogenized 1min and kidney samples 
40 s at max speed at 4˚C. Debris was pelleted by centrifugation (1500rmp, 5 min, 4˚C). Viral titter was determined by 
standard plaque assay on MDCK cells as described before (Methods 1.2). 
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5.5. Preparation of lung cell suspension 
Upper left lungs were kept in RMPI medium at 4˚C. Tissue samples were grinded into very small pieces prior to 
digestion with 180 µg/ml liberase (Roche) and 40 µg/ml DNase I (Roche) in RMPI medium for 30 minutes at 37˚C. 
Digested fragments were filtrated with 40mm Nylon Cell Strainer (BD Falcon) and resuspended with RMPI-3%FBS. 
After the centrifugation of samples (1640 rmp, 5 min, 4˚C) additional step for erythrocyte lysis were performed. Cell 
pellet was incubated for 1.5-2 min with 1ml of erythrocyte lysis buffer (Material 6) at RT.  Lysis is inhibited by adding 
9ml of PBS-5mM EDTA-3%FBS. Samples were then filtrated again with 40mm Nylon Cell Strainer and pelleted by 
centrifugation (1640rmp, 5 min, 4˚C).  
5.6 Flow cytometry analysis   
 
Cell suspensions were distributed in 96 wells plate and first incubated with violet LIVE/DEAD due (Invitrogen) for 30 
min at 4˚C, washed 2 twice with PBS and then incubated for 15 min at 4˚C with Fc block CD16 rat antibody.  Samples 
were analysed by staining cell suspension with conjugated antibodies (Table 5) with 30 µl antibody mix in 1XPBS for 30 
minutes at 4˚C in the dark. Samples were than fixed by incubation with 4% formaldehyde for 20 min, pelleted by 
centrifugation (700 rmp, 5 min, 4˚C) and washed once with PBS. After centrifugation (700 rmp, 5 min, 4˚C), cells were 
resuspended in 0.4ml PBS and kept at 4˚C O/N in the dark. Flow cytometric analysis was performed on a cytometer 
LSR II (BD Biosciences).Data were analysed using CellQuestPro software.  
 
  
  
 
 
 
 
Table 5. Antibodies used for cell suspension staining 
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1. Study of the contribution of changes found in the F viral strain to its pathogenicity in vitro and in vivo 
 
To characterize the putative F virus virulence determinants, we generated recombinant influenza viruses bearing HA 
S127L, PB2 A221T (CAL-PB2) or PA D529N mutations (CAL-PA) or the combination of these changes (CAL-PB2/PA; F 
virus-like polymerase) in the A/California/04/09 (CAL) as backbone. CAL virus is one of the first swine-origin H1N1 
influenza virus isolated from a 10-year old patient in the USA. Viral particles of this virus are more filamentous than 
other H1N1 strains. CAL virus is shown to be more pathogenic in infected mammals (mice, ferrets and non-human 
primates) than contemporary H1N1 strains (Itoh, Shinya et al. 2009). It is oseltamivir and zanamivir sensitive but, as all 
pandemic strains are, amantadine resistant (Swiss Institute of Bioinformatics 2009). To test if any of detected changes 
was responsible for the behaviour of the F strain, the growth kinetics of these viruses were analysed in human 
alveolar A549 cells (Methods, 1.2). Statistical analysis were performed by unpaired, two tailed Student t-test.* p<0, 
05.             
 
 
All recombinant viruses, including CAL-PB2/PA (F-like-polymerase virus) showed similar growth rate and viral titers at 
72 hours of infection (Figure 10). The CAL-PB2 recombinant virus had a lower growth rate than others, which is 
statistically significant only at 36 hours of infection, when compared to both CAL and CAL-PA recombinants. All 
recombinants bearing mutation in HA segment, single or in combination with others, showed a tendency of reaching 
higher viral titers from 24 to 48 hours upon the infection, although this growth rate was not statistically significant 
(data not shown). 
Increased polymerase activity constitutes an important virulence factor in influenza virus. In order to examine if any of 
these mutations in PA and/or PB2 polymerase subunits modify the viral polymerase activity, we performed in vivo 
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Figure 10. Growth kinetics of recombinant viruses in human alveolar cells. A549 cell line was infected at moi 10
-3 
pfu/cell for 72 
hours. Samples were obtained at different time points for estimation of viral titer. Viral yield was determined by plaque assay in 
the MDCK cells at different time points. 
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reconstitution of viral ribonucleoproteins (vRNPs). Cells were transfected with plasmids expressing the wild-type or 
mutant polymerase subunits and NP together with a plasmid that expresses a flu-like chloramphenicol 
acetyltransferase (CAT) in negative sense orientation. The CAT enzyme can only be transcribed if viral polymerase 
complex if fully functional in transfected cells. The viral polymerase activity is determined as the relative CAT 
accumulation which is measured by CAT enzyme activity (Methods 4.1).  
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Similar CAT activity was observed in all reconstituted RNPs, suggesting that neither single mutations PB2 A221T or PA 
D529N nor both of them together, affect the activity of the polymerase complex in transfected cells (Figure 11). Both 
results indicate that none of the evaluated mutations or combinations of them (Figure 10) incorporated in 
Cal/04/2009 H1N1 pandemic strain backbone are  responsible for F strain virulent phenotype in cell culture.  
 
 
 
 
 
 
 
 
 
Figure 11. Relative polymerase activity of wild-type or mutant reconstituted RNPs. HEK293T cells were transfected with plasmids 
expressing CAT in antisense orientation, NP, PB1, and wtPB2 and wtPA (CAL), or the corresponding subunits expressing mutated 
PB2 A221T (CAL-PB2), mutated PA D529N (CAL-PA) or mutated PB2 A221T and PA D529N (CAL-PB2/PA). At 24 h post-
reconstitution, CAT protein in total cell extracts was analysed by ELISA. In MOCK, plasmid expressing PB1 was omitted. pNS-CAT 
indicates CAT accumulation in cells transfected exclusively with pHHNS-CAT plasmid. Three independent experiments were 
performed; values shown as means (%) ± SD. Statistical analysis done by unpaired, two tailed, Student t-test showed no significant 
differences in polymerase activity of these recombinants. 
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2. Characterization of recombinant viruses containing changes present in the F isolate in mouse infection 
model 
2.1 Determination of LD50   
It has been previously described that in animal model, theF virus was more pathogenic than the M, causing significant 
weight loss and 50% survival drop by the 6
th
 day of infection (Rodriguez, Falcon et al. 2013). Since there was no 
correlation between the virulence of particular recombinant virus and the F strain in infections in cell culture, we 
performed in vivo experiments to evaluate the effect of mutations in more complex infection system. To evaluate the 
pathogenicity of the recombinant viruses, mice were intranasally infected with various doses of the different 
recombinant viruses.  Body weight loss, as a symptom of illness (Figure 12), and survival rate (Figure 13) were 
monitored daily for two weeks. Viral dose that causes 50% of mortality (LD50) was calculated for each recombinant 
virus (Methods 5.2.) 
 
Using high viral doses of infection, we observed that mice infected with recombinant viruses that carried HA change 
and PB2 change showed signs of mild illness which induced lower weight loss when compared to CAL recombinant 
(Figure 12). These recombinants (CAL-HA and CAL-PB2) showed completely different pathogenicity pattern in murine 
model than viruses with PA change in its genome.  
 
 
 
 
 
 
 
Table 6. Evaluation of pathogenicity of recombinant viruses in mice. Balb/C female mice (n = 4) were inoculated intranasally with 
10
6
–10
2 
pfu of each recombinant virus. The dose that causes 50% mortality of mice in each infection (LD50) is shown. 
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CAL, CAL-HA, CAL-PB2, CAL-PA and CAL-PB2/PA viruses showed LD50 of 1.6 x 10
5
, >10
6
, >10
6
, 3 x 10
3
 and 3.5 x 10
4
, 
respectively (Table 6). These data confirmed that CAL virus is pathogenic in mice, as it has been previously shown 
(Itoh, Shinya et al. 2009), and indicated that the PA D529N mutation greatly increases its’ pathogenicity, suggesting a 
decisive effect of this polymerase change on disease outcome.  CAL-PB2 and CAL-HA were greatly attenuated 
compared with the CAL strain.  Furthermore, all recombinants that carried HA change alone or in combination with 
others changes in PA and PB2 gene segments, showed decreased pathogenicity in murine model (Table 6). These data 
indicate that mutation detected in HA segment of F viral strain is not responsible for its pathogenicity in mice. 
Therefore, recombinant viruses with HA mutation have been excluded from further in vivo studies. On the other hand, 
reconstitution of the F-like polymerase-containing virus (CAL-PB2/PA) led to lower pathogenicity compared with CAL-
PA virus. 
 
 
 
 
Figure 12.  Pathogenicity of recombinant viruses in in vivo infections. Mice (n = 4) were intranasally infected with different viral 
doses and monitored for weight loss as a sign of infection during 14 days. Due to ethical reasons animals were euthanized when 
they lost 25% of their original body weight. 
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These data show that recombinants with the PA mutation present in the F strain are more pathogenic in mice 
experimental model. PA mutation alone or together with PB2 mutation, retains the lethal phenotype showed by F 
strain in mice model and recombinants with PA or both PA and PB2 mutations cause more mortality than control CAL 
virus. Summarizing, introduction of PA D529N mutation in Cal/04/09 strain increases its pathogenicity in vivo. 
Moreover, a viral dose that drops survival rate 50% in mice infected with the F strain is lethal in animals infected with 
CAL-PA virus. CAL-PA recombinant virus is even more pathogenic in the mice model than F strain.  
Pathogenicity of influenza virus depends on various and complex features. Final outcome of infection involves several 
factors such as the nature of the virus and the host and their interplay. To further evaluate the differences in the 
pathogenicity of these viruses, mice were infected with a sub lethal dose of the recombinant CAL, or the different 
recombinant viruses, or were mock-infected (Methods 5.2). Tissue samples were collected on the 1
st
, 2
nd
, 4
th
 and 7
th
 
day post-infection (dpi) to determinate viral titers, viral spread, genome expression and immune response (Methods 
5.3- 5.5). Each lung was divided into 4 samples:  superior and post-caval lobes were used for determination of viral 
titers, inferior and middle lobes for RNA extraction while left lung was divided into 2 samples. Upper left lung lobe was 
used for flow cytometry analysis of innate immune response and lower left lobe for histological analysis (Figure 14).  
 
 
 
Figure 13. Pathogenicity of recombinant viruses in in vivo infections. During 14 days of infection, survival rate was monitored on 
mice (n = 4) intranasally infected with different viral doses. Due to ethical reasons animals were euthanized when they lost 25% of 
their original body weight.   
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The detection of H1N1 influenza virus in organs different from the lung, such as kidney has been described (Watanabe 
2013), as well as heart dysfunction for severe influenza H1N1 infected patients (Komai, Nakazawa et al. 2011, 
Jeyanathan, Overgaard et al. 2013). Additionally we have previously described the presence of infectious particles in 
higher proportion and remaining at later dpi in the hearts of F virus compared to M virus infected mice (Rodriguez, 
Falcon et al. 2013). Therefore, we tested the possible presence of the different influenza recombinant viruses in these 
organs, in addition to lungs. 
2.2 Replication of recombinant viruses in lungs of infected mice 
 
Viral replication in lungs was evaluated at several points during the infection. Lungs lobes weight were measured and 
diluted in PBS-BSA (Methods 5.4). Data are presented as the pfu per grams of tissue. The weight of superior and post-
caval lobes used for determination of viral titer was measured to examine possible liquid accumulation or other tissue 
damage caused by an inflammation process in infected lungs. Results presented in Figure 15, show lower lung weights 
of mice infected with CAL-PA virus but with differences not statistically significant.  
Figure 14. In vivo analysis of recombinant virus infection. Balb/c Mice (n = 5) were infected with a sublethal viral dose (10
3
 pfu) of 
each recombinant virus. Organs were collected at different time points of infection in order to analyse pathogenicity and viral 
spread capacity of each recombinant virus. 
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Data show the highest viral titers in mice infected with CAL-PA recombinant virus (Figure 16).  
 
Interestingly, viral titer of CAL-PA recombinant is not significantly higher than CAL and CAL-PB2/PA viruses at early 
infection (1 dpi). Recombinant virus CAL-PB2 produced low viral titers throughout all the infection, which were 
significant, compared with the recombinant Cal/04/09 virus.  
 
 
 
Figure 15. Weight of superior and post-caval lung lobes. Samples were used to examine possible liquid accumulation or other 
tissue damage caused by an inflammation process in infected lungs.   
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Figure 16. Viral titer in the lungs of infected mice. Mice (n = 5) were inoculated intranasally with a sub lethal dose (10
3
 pfu) of 
each recombinant virus or PBS (MOCK) as control.  At indicated dpi, viral titers were determined in the lungs (pfu/g tissue) by 
plaque detection in MDCK cells, statistical analysis was performed by unpaired, two tailed, Student t-test *** p<0.0001, ** 
p<0.005, *p<0.05 
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2.3 Replication of recombinant viruses in extra-pulmonary organs of infected mice 
 
Influenza A virus can spread to extra-pulmonary organs, which may contribute to its pathogenicity. Previous study 
showed that F virus was capable of spreading outside lung tissue in animal model (Rodriguez, Falcon et al. 2013, 
Watanabe 2013).  
Analysing our data (Figure 12 and 13) we observed a high mortality in animals infected with high doses of CAL-PA 
recombinant, that occurred in mice which did not get below 77% of original weight and did not reach the limited 25% 
weight lost (Table 7). In fact, animals infected with CAL and CAL-PB2/PA recombinants with the same high viral doses, 
lost weight faster than animals infected with CAL-PA recombinant, and only one CAL-PB2/PA infected mouse suffered 
sudden dead. This might indicate that besides usual symptoms, infection with recombinant viruses containing PA 
mutation causes atypical health conditions and sudden death in infected animals. 
 
It has been reported that influenza infection can induce serious heart dysfunctions in patients as well as acute viremia. 
Thus, we monitored possible viral spread into extra-pulmonary tissues with focus on highly vascularized organs such 
as kidney and heart. First, we evaluated infection of kidneys (Figure 17) by the different recombinant viruses. Viral 
titer was determined by plaque detection on MDCK cells and viral particles were not present in kidney samples of any 
infected animal.  
Table 7. Animals infected with CAL-PA recombinant virus experiencing sudden death early in infection. Mice (n=4) were 
intranasally infected with 10
6
 pfu viral dose.  Weight loss of animals infected with CAL, CAL-PA and CAL-PB2/PA recombinant 
viruses at several days post-infection is expressed taking as 100% the initial weight before infection. The boxed data belong to 
mice presenting sudden death. 
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Seasonal infection may cause severe illness and death in patients with previously diagnosed heart conditions. Even in 
the healthy individuals influenza infections may lead to serious cardiovascular dysfunctions that may include 
myocarditis, acute myocardial infarction and hypertrophic cardiomyopathy (Mamas, Fraser et al. 2008, Komai, 
Nakazawa et al. 2011). Additionally, it has been previously shown in our laboratory the presence of viral particles in 
the heart of mice infected with the F strain on the 2
nd
 and 4
th
 day of infection (Rodriguez, Falcon et al. 2013). Thus, 
both, heart weights and viral titer in hearts were examined at different stages of infection with the different 
recombinant viruses. 
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 No significant differences in heart weight of infected animals in any group were found suggesting that no severe heart 
inflammation occurred after infection.    
Figure 18. Hearts weight of the mice infected with the different recombinant viruses. Hearts of mock and influenza-infected 
mice at different time points of infection were excised and weighed; Statistical analysis was performed by unpaired, two tailed 
Student t-test. 
 
Figure 17. Kidneys weight of the mice infected with the different recombinant viruses. Kidneys of mock-  and influenza-infected 
mice at different time points of infection were excised and weighed; Statistical analysis was performed with unpaired, two tailed 
Student t-test. 
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On 1
st
 day after inoculation all animals infected with CAL-PA virus presented infectious particles in the heart, while 40 
% of mice infected with CAL-PB2/PA and CAL recombinants had viral particles in this organ. By the 2
nd
 day, 80% of CAL-
PA, CAL-PB2/PA and CAL infected animals, presented infectious particles in their hearts; at this day the attenuated 
CAL-PB2 virus, reached its maximum value of 60%. The percentage of hearts containing viral particles declined and on 
the 4
th
 day post-infection, only CAL and CAL-PA infected mice were positive (20% and 60% respectively) to viral 
presence in heart tissue. By the 7
th
 day all animals were negative for virus detection in the hearts. Having into account 
the total number of mice having viral particles in the hearts between 1 and 4 days of infection (Figure 19b), 46,7% of 
CAL-infected mice were positive and this number raises to 80% for CAL-PA infected animals. Therefore, infectious viral 
particles can be found with higher frequency and at prolonged period of time in mice infected with the high 
pathogenic CAL-PA recombinant virus. 
Figure 19. Recombinant viruses are able to infect heart tissue. (a) Viral titer in hearts of infected animals. Every point 
represents viral yield found in each infected animal. Samples without viral particles were given a value of 1. (b) Percentage of 
infected mice having viral particles in hearts until 4
th
 day of infection. 
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Comparing the presence of infectious particles in lung and heart of infected mice, it can be observed a lack of 
correlation of viral titers in both organs. This can be observed in data from Figure 21b, for instance on the 4
th
 day post-
infection there are infectious particles in the lung of all mice (Figure16), whereas only CAL and CAL-PA infected mice 
have virions in their hearts (Figure 20). Therefore, simple viral transmission is ruled out as the cause of viral detection 
in hearts. These results suggest that pathogenicity of recombinant viruses carrying PA mutation may be increased by 
the fact that animals infected with these viruses have a prolong exposure to higher viral titers in hearts than other 
groups.  
Next we examined whether infectious viruses present in the hearts were the consequence of viral replication inside 
this organ. Although viral titers in lungs do not correspond to viral titers in hearts, it cannot be excluded that viral 
particles found in heart were due to circulation derived from infected lungs given the proximity of the two organs, and 
high blood circulation. To analyse if hearts’ viral particles were the result of viral replication within this organ we 
performed a qPCR to detect NEP mRNA (Methods 3.3.1). 
The mRNA of NEP is a spliced mRNA transcribed from NS viral segment and it is only present in cells with ongoing viral 
transcription (Introduction 2.5).   
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Figure 20. Viral titer in heart samples of animals infected with the different recombinant viruses. Mean and SD of viral titers 
detected in the hearts of mice infected with CAL wild-type or mutant recombinant viruses.  Statistical analysis were performed 
with unpaired, two tailed Student t-test showed no significance in viral titer in heart samples 
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The mRNA of NEP was detected in hearts where infected particles were found, indicating that the recombinant viruses 
are able to infect and replicate in the heart of infected mice. This characteristic of recombinant viruses may contribute 
to their pathogenicity especially in the CAL-PA recombinant virus, since animals infected with this virus have virus 
capable of heart infection at highest titers and at longer period of time than other infected animals. 
2.4 Immune response in lungs of infected mice 
 
Virus pathogenicity depends on the nature of the virus, the host conditions and its rapid and adequate response to 
the infection. To see if these recombinant viruses produced different immune response we monitored innate immune 
cells influx (neutrophils, alveolar macrophages, monocytes etc.) in infected lungs at early stages of sub lethal infection 
by flow cytometry analysis (Methods 5.5 and 5.6). For significance analysis of differences between groups we used 
regular two-way ANOVA statistical analysis with Bonferroni post-test.  
- Neutrophils are the first cells to be recruited upon viral infection and its influx is crucial for development of diseases 
and severity of inflammation process. 
 
 
 
 
 
 
Figure 21. Recombinant viruses are able to replicate in heart tissue of infected animals. (a) Transcript products from NS viral 
segment. Arrows depict the primers, forward primer fusion (red) and reverse primer (green) used for detection of NEP mRNA (b) 
Viral titers found in hearts and the corresponding viral titer in lungs of same infected animals on the 2dpi. Presence of NEP mRNA 
in samples with viral titer in hearts and absent in negative samples is shown. 
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The neutrophils influx is presented in Figure 22. On the 2
nd
 day of infection influx reaches its maximum levels in 
recombinant viruses with PA mutation (CAL-PA and CAL-PB2/PA) while infiltration in lungs of animals infected with 
CAL-PB2 recombinant remains at the same level than control CAL virus. Further on, the only animals that maintain 
significant influx compared to that infected with control CAL virus on the 4
th
 day, are that infected with CAL-PB2 virus. 
In summary animals infected with recombinant viruses that have mutations in PA polymerase subunit (CAL-PA and 
CAL-PB2/PA viruses) cause dramatically high influx of these cells on the 2
nd
 day of infection.  
- Alveolar macrophages are the first cells to detect pathogens in lungs and are target cells for influenza infection.  
 
The results of alveolar macrophages influx are presented in Figure 23. There is a significant displacement of alveolar 
macrophages to the left upper lung lobe in recombinant viruses-infected mice compared to that of the mock-infected 
animals at the beginning of the infection (1
st
 dpi).  On the 2
nd
 day of infection the level of alveolar macrophages in 
attenuated recombinant virus (CAL-PB2) infected mice remains unchanged, while animals infected with more 
pathogenic recombinant viruses (CAL, CAL-PA, CAL-PB2/PA) show the same level as the mock infected mice. By the 4
th
 
day of infections there are no significant differences in the level of alveolar macrophages in all infected animals. Even 
though first response of alveolar macrophages to infection is the same, the level of these cells dramatically drops on 
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Figure 22. Neutrophils. Influx of neutrophils (cells expressing Ly6GPE
+
CD11b
+
CD45
+ 
receptors gated in dot plot) into the infected 
lungs throughout the infection *** p<0.0001, *p<0.05 
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Figure 23. Alveolar macrophages. Influx of alveolar macrophages (cells expressing CD11c
+
CD45
+
autoflorescence
+
 gated in dot 
plot) in the infected upper left lung lobe; Statistical analysis have been done by two-way ANOVA statistical analysis with 
Bonferroni post-test ***p<0.0001, **p<0.005, *p<0.05 
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the 2
nd
 day of infection in lungs of mice infected with more pathogenic viruses. This may indicate that besides alveolar 
pneumocytes, alveolar macrophages might be widely infected at the beginning of the infection in these animals, 
which might delay activation of adaptive immune response increasing the pathogenicity. 
- Dendritic cells (DCs), besides macrophages, are professional antigen presenting cells, and very important in 
activation of adequate adaptive immune response in infections. We monitored the influx of conventional DCs in the 
upper left lung lobe of infected mice at several days post-infection.  
  
 
Similar to alveolar macrophages at the first day of infection we observed significant influx of presumably conventional 
DC in all virus-infected compared to mock-infected animals, except for CAL infected ones (Figure 24). On the 2
nd
 day of 
infection influx of DCs in animals infected with recombinant viruses with PA mutation show significantly higher levels 
of DCs in upper left lung lobe than other infected groups.  All throughout infection, mice infected with the 
recombinant CAL virus showed the same level of conventional DCs as uninfected group. Attenuated recombinant virus 
(CAL-PB2) provoked significant influx of DCs compared to uninfected group on the 1
st
 and 4
th
 day of infection, which 
may be due to activation of adequate adaptive immune response in these mice. Even though levels of conventional DC 
lowers during the infection in these animals they are still highly significant when compared with both uninfected and 
CAL infected groups. This suggests that infection with both CAL-PA and CAL-PB2/PA recombinants led to higher influx 
of conventional dendritic cells in upper left lung lobes of infected animals with an utmost peak on the 2
nd
 day of 
infection.  
All virus-infected animals showed influx of DCs; only those infected with the most pathogenic viruses (carrying PA 
mutation, CAL-PA and CAL-PB2/PA) showed a significantly higher amount of DCs on the 2
nd
 day of infection.  
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Figure 24. Dendritic Cells. Influx of conventional dendritic cells (cells expressing CD45
+
CD11b
+
 yet not CD11c
-
Ly6GPE
- 
selected in 
the left
 
gate in the left dot plot separated by its size and complexity right dot plot) into the infected lungs; Data were analysed 
with two-way ANOVA with Bonferroni post-test *** p<0.0001, ** p<0.005, *p<0.05 
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Table 8. Inflammation process in infected mice lungs . Expression of pro-inflammatory cytokines and chemokines in infected 
lung tissue with CAL and CAL-PA viruses; significance analysis was performed with FIESTA. 
- Monocytes have the ability to differentiate in both macrophages and monocyte derived dendritic cells (mDC) in the 
ongoing infection. Due to their importance in the immune response, the influx of these cells was analysed in the 
infected animals. Since, specific antibodies for monocytes or dendritic cells were not used in this experiment, we 
separated these two cell population by size and complexity.  
 
The results of influx of monocytes are presented in Figure 25. No significant differences were found on the 1
st
, 4
th
 and 
7
th
 day of infection among the mice infected with the different recombinant viruses, whereas significant differences 
were observed on the 2
nd
 day of infection. The reference recombinant CAL and the CAL-PB2/PA viruses had 
significantly higher influx of these cells on the 2
nd
 day of infection than other infected groups. Since influx of 
conventional DCs has not been detected in CAL infected animals, higher level of monocytes might be an attempt to 
attain normal DC immune response by induced differentiation of monocytes into dendritic cells mDC.  
- Inflammation. To study differences in inflammation process we analysed the expression of cytokines and 
chemokines in mice infected with the reference CAL virus and with the virus with the highest pathogenicity (CAL-PA) 
at 2dpi (Methods 3.4). The results are presented in Table 8.  
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Figure 25. Monocytes. Influx of monocytes (cells expressing CD11b
+ 
yet notCD11c
-
Ly6GPE
-
 selected in the left
 
gate in the left dot 
plot separated by its size and complexity right dot plot) into the infected lungs; Statistical analysis were performed with two-way 
ANOVA with Bonferroni post-test ***p<0.0001, **p<0.005, *p<0.05 
 
 
76 
 
 
Chemokines responsible for infiltration of monocytes (MCP1, MCP3, Cxcl10), macrophages (MIP-1α, MIP-1β), 
neutrophils (Csf3), T cells (Ccl19, Cxcl9, Cxcl10, Cxcl11) and B cells (Ccl19, Cxcl13) are overexpressed in lung tissue of 
CAL-PA compared to CAL infected animals (Table 8). Overexpression of Ly6G in CAL-PA infected lungs indicates high 
infiltration, recruitment and migration of neutrophils. Ccr5 overexpression (CD195) in T cells, DC and macrophages of 
CAL-PA infected animal indicates acute inflammatory state in infected lung. All these data correlate with flow 
cytometry study and prove higher inflammation process in CAL-PA compared to CAL infected mice.  Higher expression 
of serum amyloid A genes imply severe inflammation in infected lungs since these proteins have been conferred as 
biomarkers of acute inflammation in patients with chronic obstructive pulmonary disease (Calero, Arellano et al. 2014, 
Sun and Ye 2016). 
3. Antiviral response in human infected cells 
 
Recombinant viruses induce different innate immune response, which strictly correlates with their previously 
determined pathogenicity and mortality in vivo. CAL-PA and CAL-PB2/PA recombinant viruses that were the most 
pathogenic in the mice model were also able to induce higher innate immune response, higher titers in both lungs and 
hearts, and stronger influx of immune cells and inflammation that may contribute to its overall pathogenicity. 
To examine if the same outcome can be achieved in infections of human cells we infected human alveolar A549 cells 
with the different recombinant viruses and with an influenza virus lacking NS1, a viral protein mainly involved in 
counteract immune response, as control virus (Garcia-Sastre, Egorov et al. 1998). The induction of antiviral genes and 
accumulation of viral proteins were analysed 16 and 24 hours post-infection (Methods 3.3.1 and 4.2).  
  
The results show that accumulation of ISG56 and MxA 16 hours after infection is clearly detectable in cells infected 
with the low pathogenic virus CAL-PB2, while cells infected with CAL-PA, CAL-PB2/PA and CAL viruses have less 
accumulation of these proteins. CAL-HA infection induces expression of ISG56 and MxA later than any other 
recombinant even though it has a similar replication rate compared with the others recombinants. In the in vitro 
Figure 26. Accumulation of antiviral proteins MxA and ISG56 and viral NP protein. Cultured A549 cells were infected at 0.5 moi 
with the recombinant viruses. At the indicated hpi, samples were used to detect the indicated proteins by Western blot. MOCK; 
cells treated with PBS as negative control. ΔNS1; cells infected with a virus lacking NS1 protein (Garcia-Sastre, Egorov et al. 1998) 
IFN; cells treated with 1000u/ml of IFNα2 as positive controls 
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infection, with those recombinant viruses that were more pathogenic in mice, there is a significant subtle delay in 
ISG56 accumulation compared with the infection with attenuated CAL-PB2 virus and positive controls (Figure 26).  
To further evaluate the slight differences observed in the accumulation of antiviral proteins, additional experiments 
were performed analysing the expression of the corresponding genes in A549 respiratory cells by qPCR. The mRNAs 
for MxA and ISG56 genes were determined in the cells infected with the different recombinant viruses. Additionally, 
to evaluate the correlation of the induction of these genes with their putative inducer, levels of IFN-β gene were also 
determinate in this same assay. 
 
 
 
 
 
Figure 27. Relative amount of the indicated mRNAs in A549 cells infected at moi 0.5 with the different recombinant viruses. 
Expression of (a) MxA, (b) ISG56 and (c) IFN-β genes during the first 12 hours of infection. The values obtained in CAL-infected cells 
are taken as 100% and the amount of rRNA28S was used to normalize every determination. (d) Control of kinetics of infection for 
every recombinant viruses in A549 cells performed by WB against the indicated proteins 4,8,12 hours post-infection. Statistical 
data were analysed by unpaired, two tailed Student t-test ***p<0.0001, **p<0.005, *p<0.05 
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The quantitative data (Figure 27) correlate with the results obtained for protein accumulation 16h after infection 
showed in (Figure 26). CAL-HA recombinant does not induce antiviral response efficiently as the other viruses do. 
Recombinant CAL-PB2 virus induces the highest expression of antiviral genes, while interestingly, previously described 
more pathogenic CAL-PA virus induces less antiviral response than CAL-PB2. PA mutation is able to reduce the 
activation of antiviral response of the CAL-PB2, as it is shown by recombinant virus bearing both PA and PB2 
mutations (CAL-PB2/PA; F-like-polymerase virus). Although at the beginning of infection induction of IFN-β in cells 
infected with CAL-PA virus is higher than that of CAL virus, the same level of induction is observed at later time of 
infection (8 and 12 hpi). Induction of MxA and ISG56 is significantly lower before the end of the first viral cycle in CAL-
PA virus infected cells. This is observed 4 and 8 hours upon infection in the case of MxA gene and  8 hpi in the case of 
ISG56 gene compared with our CAL control (Figure 27). This suggests that previously described more pathogenic 
recombinant CAL-PA virus induces less antiviral response in human pneumocytes than other recombinant viruses in 
early stage of infection, with an exception of CAL-HA virus that does not induce antiviral response at all, even though 
all of these viruses replicate at the similar level in the first 12 hours of infection (Figure 27d). 
4. Role of defective genomes (DGs) in viral pathogenicity 
 
Interesting results from previous experiments indicated that CAL-PA recombinant keeps the same level of replication 
than the other recombinant viruses in A549 infected cell and yet restrains antiviral response of these cells. A possible 
explication for this characteristic of CAL-PA virus could be that its polymerase, even though does not possess higher 
activity than that of the others recombinant viruses, has higher fidelity and/or stability of the complex itself. This 
would lead to fewer errors during replication process, lower production of defective genomes (DGs) and partial 
inhibition of antiviral response in infected cells. To address this possibility we analysed DGs generation of all 
recombinant viruses. 
Production of DGs was previously detected in both cell culture and mice infected with F and M strains. Deep 
sequencing showed that M strain generates more than 7 fold higher amounts of DGs than F strain. Furthermore, 
although not quantitative, simple PCR analysis indicated that ratio between full-length viral genome and DGs in both 
PB2 and PA segments was higher in the lung samples of more pathogenic F virus infected mice than in M-infected 
mice (manuscript under review).  Since, production of DGs is a by-product of replication; viral polymerase plays a key 
role in its generation. Therefore, changes detected in the viral polymerase subunits of F strain may contribute to lower 
DGs production.  
To investigate this possibility we performed deep sequencing analysis. Recombinant viruses were grown in cell 
culture, viral particles were purified from cell supernatants followed by RNA isolation that was used for deep 
sequencing using the same criteria for defining DGs applied in F and M isolates (Methods 3.4).  
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The data showed that CAL virus accumulates low DGs levels, which coincides with the reported high virulence of the 
CAL reference strain (Itoh, Shinya et al. 2009), and is similar to the F virus.  The CAL-PB2/PA and CAL-PA viruses 
showed DGs accumulation similar to CAL virus (2.6- and 1.3-fold change, respectively; Figure 28), whereas CAL-PB2 
had a 27-fold higher DGs ratio than CAL virus, which was almost 11-fold higher than CAL-PB2/PA (with the F-like 
polymerase). These data indicated that the PB2 A221T mutation enabled high DGs accumulation (Figure 28; compare 
CAL vs CAL-PB2), whereas PA D529N mutation restricted their accumulation (Figure 28; compare CAL-PB2/PA vs CAL-
PB2).  The combination of PA and PB2 changes, which mimics F virus polymerase, leads to low DGs accumulation, as 
also observed for the F virus itself (Figure 7). 
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Figure 28. Defective genomes in purified viral particles of recombinant viruses. Recombinant viruses were grown in MDCK cells 
at 10
-5
 moi and collected after 36 hours of infection. DGs ratios are calculated as jumping reads per million (RPM) that align the 
viral genome compared with entire genomes, analysed in purified virions of recombinant viruses. DGs ratio of the CAL 
recombinant virus is taken as 1 and fold change is shown for the mutant viruses versus CAL. 
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We also determined DGs distribution per viral segment for all the recombinant viruses (Figure 29).  
 
We found that DGs distribution per viral segment was random in the majority of the viruses.  Although the majority of 
DGs are produced in the polymerase segments (PB1, PB2 and PA), as previously described, certain viruses also 
generate large numbers of DGs in other segments (Figure 29). This is particularly observed in CAL virus, which 
generates DGs mainly in the NS segment, for reasons that remain unclear. This suggests that not just quantity but 
origin of generated DGs can play an important role in influenza virus infections and its outcome. Nevertheless, CAL-PA 
recombinant virus retained the F strain phenotype producing a low DGs production capability. 
Accumulation of DGs has been described in in vivo viral infections (Saira, Lin et al. 2013). To test whether the distinct 
capacities of these viruses to accumulate DGs could be observed in vivo, we analysed DGs and viral genome 
accumulation in the lungs of recombinant viruses-infected mice on the 2
nd
 dpi by PCR analysis (Methods 3.3.2). For 
that two separate PCR reactions were made; one for detection of defective genomes and other that detects an 
internal fragment of the entire viral gene segment that is absent in DGs. Since defective genomes originate vastly from 
polymerase genes (PB1, PB2 and PA) we focused on PB2 and PA segments and their DGs. 
Figure 29. Distribution of generated DGs per viral segment of recombinant viruses. DGs for each viral segment in the 
recombinant viruses is calculated as jumping RPM that align each viral RNA segment.   
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Similarly to cell culture infection, in in vivo infection the recombinant viruses generated defective genomes from PB2 
and PA segments and packed them within the viral particles. Although this is not a quantitative technique, the ratios 
between amplified internal segments and DGs, suggest that CAL and CAL-PA recombinants produce lower amounts of 
DGs from PB2 and PA segments than the other recombinants in in vivo infection.   
 
To confirm that PA change found in F virus plays a major role on the ability to reduce the accumulation of DGs and 
that this behaviour contributes to pathogenicity, we took advantage of previously described mutations in matrix 1 
(M1) and matrix 2 (M2) viral genes enabling influenza virus to accumulate large amount of DGs (Perez-Cidoncha, Killip 
et al. 2014). Thus, recombinant CAL viruses carrying these M1/M2 mutations in the presence or absence of PA change 
were generated (CAL-M and CAL-M-PA viruses, respectively). Deep-sequencing of RNA obtained from CAL-M and CAL-
M-PA purified virions was performed.  A forty four-fold increase of DGs in CAL-M compared to CAL virus was observed 
(Figure 31) in accordance with the previously described capacity of these changes to increase DGs in an H3N2 
influenza virus context. The change D529N in PA gene (CAL-M-PA virus) decreased the DGs ratio of the parental virus 
(Figure 31).  
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Figure 31. Production of DGs in recombinant viruses carrying mutations in the M and the PA segments. Recombinant viruses 
CAL-M and CAL-M/PA were grown in MDCK cell line at 10
-5
 moi for 36 hours. The DGs ratios are calculated as jumping RPM that 
align the viral genome, analysed in purified virions of recombinant viruses. DGs ratio of the CAL recombinant virus is taken as 1 
and fold change is shown for the mutant viruses versus CAL. 
Figure 30. Detection of DGs and internal fragments from full length PB2 and PA genome segments in virions isolated from 
lungs of infected animals. 
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The DGs distribution per viral segment for these viruses is shown in Figure 32. Introduction of PA mutation in CAL-M 
virus drops production of DGs especially in M, PA and NA segments. CAL-PA, CAL-M and CAL-M-PA recombinants 
generated low amounts of DGs from NS segment in contrast to CAL reference virus. These data suggest that the origin 
of some DGs may play a role in phenotypic manifestations. 
 
As shown in Figure 31, introduction of PA D529N mutation in CAL-M virus increases production of DGs. To examine 
whether accumulation of DGs modifies the pathogenicity of recombinant viruses carrying M and both M and PA 
mutation, the pathogenicity of the CAL-M and CAL-M-PA recombinants was studied by estimation of LD50 in in vivo 
experiment (Figure 33a). 
 
Figure 32. Distribution of generated DGs per viral segment of Cal-M and CAL-M/PA recombinant viruses. Viral particles from 
each recombinant virus were purified from viral stocks generated at moi 10
-5
 pfu/cell after 36 hours of infection. DGs for each viral 
segment in the recombinant viruses in Fig.29, is calculated as jumping RPM that align each viral RNA segment.   
Figure 33. Pathogenicity of CAL-M and CAL-M/PA in vivo.(a) Mice (n = 5) were inoculated intranasally with 5x10
3
, 5x10
4
 and 5x10
5
 
pfu of CAL-M or CAL-M-PA.  The precise LD50 could not be determined and is represented as > the highest dose used. The LD50 for 
CAL recombinant is derived from data in Table 1. (b) Mice (n = 5) were inoculated intranasally with a sub lethal dose (5 x 10
5
 pfu) 
of each recombinant virus or PBS (MOCK) as control.  Body weights were determined daily for 10 days and are shown as the 
percentage of body weight at inoculation (time 0).  Significance was determined by unpaired, Student’s t test (* p <0.05, ** p 
<0.01, *** p <0.001). 
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Introduction of the M1+M2 mutations on the CAL or CAL-PA backgrounds led to clear virus attenuation in mice, as the 
LD50 increased from 1.6 x 10
5
  or 3 x 10
3
, respectively, to >5 x 10
5
 in both cases (Figure 33a). An accurate LD50 could not 
be calculated for both CAL-M and CAL-M/PA recombinant viruses, since they did not produce 50% survival drop at any 
viral dose that was used. In vivo infections with higher viral doses were impossible due to the experimental limitation.  
CAL-M-PA virus pathogenicity was greater than that of CAL-M virus, as weight loss in CAL-M/PA infected group is 
significantly lower in the early stages of infection (2
nd
-5
th
dpi) after sub lethal infection (Figure 33b). This suggest that 
PA mutation is a pathogenicity marker in in vivo infections, causing more serious signs of illness in infected animals, 
while M mutation attenuates its pathogenicity by extensively decreasing its LD50. These data support the idea that 
reduced DGs accumulation is a pathogenic determinant for influenza virus in mice, and that a mutated PA D529N 
derived from a fatal IAV case decreases DGs generation. 
In summary, all these results show that PA D529N mutation does not affect polymerase activity or viral replication in 
cell culture, but decreases the accumulation of DGs. This mutation increases pathogenicity of the reference strain CAL 
in animal model; causing 50% of mortality in infected animals in a 100–fold lower dose than control CAL virus and 
more than 1000-fold lower than original F strain. The increased pathogenicity conferred by PA D529N mutation is 
mediated by the contribution of several processes, including weak induction of antiviral response, weak production of 
defective genomes, high replication in the lungs, high influx of neutrophils and dendritic cells, acute inflammation in 
lungs and high incidence and replication in the hearts with possibly associated cardiac disorders. Altogether, PA 
D529N change might be responsible for the increased pathogenicity of F clinical isolate from a deceased patient. 
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Discussion 
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Influenza A virus (IAV) seasonal outbreaks and rare but severe IAV pandemics have great impact on human health and 
global economy. Vaccination is the best prevention and protection from seasonal viral infection. However, a vaccine 
inducing broad or universal protection from flu infection is still not available (Krammer and Palese 2015). In order to 
provide helpful knowledge to fight against the constant treat of emergence of highly pathogenic antiviral resistant 
subtypes of influenza A viruses, it is essential to determine features that makes some influenza A virus particularly 
virulent.   
Pathogenicity and virulence of any viral strain depends on the interplay between several features. Changes in the viral 
genome have been associated with virulence, pathogenicity and host range factor. Some specific changes lead to 
adaptation of avian strains to infect and replicate in mammalian cells as well as to increase the overall pathogenicity. 
Several of these adaptive changes have been detected in the superficial glycoprotein HA; Q226L and G228S in H2 and 
H3 strains and E190D, S137N and G225E in H1 strains (Rogers, Paulson et al. 1983, Matrosovich, Tuzikov et al. 2000, 
Ni, Kondrashkina et al. 2015). Others have been described in the other viral genes such as E627K (Subbarao, London et 
al. 1993), D701N, S714I/R (Czudai-Matwich, Otte et al. 2014) and T588I (Zhao, Yi et al. 2014) in PB2 polymerase 
subunit, N375S (Taubenberger, Reid et al. 2005) in PB1 protein, N66S (Mazur, Anhlan et al. 2008) in PB1-F2 and T85I, 
G186S and L336M (Bussey, Desmet et al. 2011) in PA subunit. Some changes in viral genome that result in 
accumulation of defective genomes (DGs) during replication (Fodor, Mingay et al. 2003), decrease the pathogenicity of 
viruses by inducing early host cells antiviral response (Tapia, Kim et al. 2013).  
These reports underline the importance of interplay of both viral and host factors in pathogenesis of influenza virus 
infection. Besides genetic viral background, host response to viral infection is equally important for the pathogenic 
phenotype of the viral strain. Appropriate and adequate immune response will prevent the viral infection disabling its 
further viral spread and controlling inflammatory process avoiding unnecessary tissue damage and injury. In this 
context, we have identified and characterized an influenza virus marker involved in high replication, but also in 
increased induction of innate immune response to viral infection and enhanced viral spread in murine model. All of 
these effects together contribute to high pathogenicity of virus and increased mortality rate in infected animals. These 
findings provide an insight into complex and multifactorial process that makes influenza A virus highly pathogenic.  
1. Pathogenesis of influenza virus 
 
During the 2009 influenza pandemic, it was observed that infection with the new A(H1N1)pdm09 viruses produced 
mild symptoms in the majority of infected patients, but compared with the previous seasonal H1N1 cases, they caused 
a greater rate of severe or complicated illness in healthy young adults and children (Louie, Acosta et al. 2009, Perez-
Padilla, de la Rosa-Zamboni et al. 2009). The co-morbid conditions were similar for both the pandemic A(H1N1)pdm09 
and previous seasonal influenza viruses and include chronic metabolic disease, primarily diabetes mellitus and renal 
disease, chronic lung and cardiac disease, immunosuppressive conditions and neoplasms (Hlavinkova, Kristufkova et 
al. 2015). In addition, obesity and pregnancy were associated to A(H1N1)pdm09 severe infections (Falagas, Koletsi et 
al. 2011, Singanayagam, Singanayagam et al. 2011). The pre-existing immune status and the existence of underlying 
chronic conditions definitely contributed to the disease outcome. However, some of the infected patients developed 
severe symptoms without any obvious impairment in health condition. Therefore, we hypothesized that different viral 
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strains during 2009 pandemics were co-circulating in human population with different pathogenicity risk to human 
health (Rodriguez, Falcon et al. 2013).  
To analyse possible virulence differences, our group compared two contemporary human A(H1N1)pdm09 viruses from 
the first wave of 2009 pandemic isolated from two patients without known co-morbid conditions and aged under 65, 
one from a patient with the fatal outcome (F) while the other showed only mild respiratory disease (M). Comparison 
of the genome of these two clinical isolates identified several changes in the virus isolated from the fatal case patient 
that have never been associated with any increased pathogenicity in Influenza A nor B viruses. These changes were 
present in the polymerase subunits (PB2 A221T and PA D529N) and the hemagglutinin (HA S127L) (Rodriguez, Falcon 
et al. 2013). Further characterization has demonstrated that none of the polymerase changes affects viral replication 
(Figure 10) or viral polymerase activity (Figure 11) in ongoing viral infection in human alveolar epithelial cells (A549). 
Pablo López in our laboratory has evaluated that the antigenic properties of HA127L are similar to wild type HA.  
Additionally, it has been shown that the entrance of vRNPs in CAL-HA127L infected cells is similar, or at least not 
faster, than CAL infected cells (data not shown). These data suggest that HA127L mutation may not alter the main 
activities attributed to this protein, such as the antigenic properties and viral entry in the cell. 
1.1. Identification of the main driving mutation of a fatal human virus pathogenesis 
 
Pathogenicity of viruses carrying the selected mutations found in F virus has been extensively evaluated. We have 
characterized the morbidity and mortality caused by recombinant viruses carrying single PB2 A221T, PA D529N and 
HA S127L changes in their genome, as well as combinations of them (Table 6). Unexpectedly, recombinant viruses 
with HA S127L mutation alone (CAL-HA) or accompanied with any other change showed no pathogenic trait and were 
attenuated compared to the control CAL virus, even though they showed tendency of reaching higher viral titer in cell 
cultures than the other recombinant viruses (Figure 10). Growth kinetics of recombinant viruses in 3T3 mouse cells 
revealed that all recombinant viruses display a similar grow rate (data not shown), while the CAL-HA virus showed a 
tendency to have lower viral titers than the other viruses in the first 48 hours of infection. Mutation HA S127L is 
positioned proximal to one of the three secondary structure that together form functional receptor binding site of HA, 
130 loop (Ping, Keleta et al. 2011, Lu, Qi et al. 2013), therefore it may be involved in the recognition of the viral 
receptor constituting a host range factor, supporting a lower production of infective particles in mouse cells infected 
with this virus. Recombinant viruses with PB2 A221T mutation (CAL-PB2) in polymerase subunit were also attenuated 
compared to parental CAL virus and showed no pathogenic feature in infected animals, except when it was 
accompanied with PA D529N mutation (CAL-PB2/PA). Therefore, mutations HA S127L and PB2 A221T do not seem to 
cooperate to the high pathogenicity of the F virus and in fact they may act as attenuation changes. 
Changes in PA subunit affect pathogenicity and virulence of influenza A clinical strains from avian origin (Yamayoshi, 
Yamada et al. 2014), moreover in 2009 pandemic strains a key role for increased pathogenicity was found in the PA 
subunit of viral polymerase (Song, Pascua et al. 2011). Recombinant virus with introduced PA D529N mutation (CAL-
PA) showed increased pathogenicity in murine model lowering the viral doses that causes 50% of mortality (LD50) 
(Table 6) by more than 300 fold compared to the parental clinical strain isolated from a deceased patient (F). This CAL-
PA feature is diminished by introduction of any other of the two selected changes found in the F lethal strain. 
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Therefore, PA D529N change is solely responsible for increased pathogenicity of recombinant CAL-PA and CAL-PA/PB2 
viruses in murine model. It is not unusual that one mutation in viral polymerase may increase the pathogenicity of 
recombinant strains, but this particular mutation has never before been associated with any increased virulence or 
pathogenicity. Furthermore, PA D529N change has been observed very scarcely among the pH1N1 strains, human 
seasonal strains, avian and swine viruses. In fact the total calculated frequency of appearance of PA D529N change in 
the influenza viruses present in these host is 0.048%, analysed using the influenza virus resource databases from NCBI. 
Cristal structure of the C-terminal domain of PA subunit revealed that several amino acids implicated in the replication 
activity of the polymerase complex (E 524, K 536, W 537) (Obayashi, Yoshida et al. 2008), are neighbouring the 529 
amino acid. This amino acid is located just in front of 310 helix, an α helix that possesses 3 amino acids (P530-R531-
L532) per turn. The 310 helix is a secondary structure, extension of α- helixes usually found in terminals of proteins or 
polypeptides. This 310 helix structures are involved in helix-coil transitions (Armen, Alonso et al. 2003). Aspartic acid 
(D), at N0 position, just in front of the 310 helix, stabilizes 310 helix structure (Karpen, de Haseth et al. 1992), therefore 
D529N mutation may destabilize 310 helix and affect helix–coil transitions of C-terminal PA domain. This helix 
transition may affect overall stability and transition from transcription to replication process of viral polymerase.  
Influenza A virus polymerase exists in different oligomerization state (Jorba, Area et al. 2008, Moeller, Kirchdoerfer et 
al. 2012), which allows different assembly of polymerase monomers during replication (Jorba, Coloma et al. 2009). 
New mechanism has been proposed for the transition of influenza virus from transcription to replication, suggesting 
that instead of one viral polymerase bound to vRNP two molecules are involved in this process. The proposed 
mechanism suggests that the RNA depending RNA polymerase (vRdRP) dimer bound to viral RNA recruits another free 
polymerase dimer to form transient tetramer, which initiates replication of viral genome (Chang, Sun et al. 2015). This 
model presumes that thumb domain of PB1 is seated on top of C-terminus of PA (PA-C) subunit, which forms the RNA 
binding and RNA polymerization active site. PA-C/PB1 interaction emphasizes the key role of the highly conserved 
charged residues in PA-C domain; K539, R566, and K574 essential for RNA binding and synthesis of all three types of 
RNA (vRNA, cRNA and mRNA), which are closely positioned to our 529 residue and 310 helix.  Residues in α5, α6, α7, 
α8 helixes, in the same domain as 310 helix of PA protein, are important for RNA binding, but also for PB1 interaction 
(E427, I428, R442, R443, R582, L586, Q590, Q591, and E593, respectively) in the tetramer sub complex (Chang, Sun et 
al. 2015). In the tetrameric structure, PB1 C terminus and PB2-N terminus are located away from the active site cavity, 
in contrast to proposed monomer state RNA synthesis mechanism (Reich, Guilligay et al. 2014). Mutation R638 in PA 
subunit that attenuates viral growth and induces production of defective genome was found in PA-C terminus domain 
(Fodor, Mingay et al. 2003). C453 and R638 mutations, both in PA-C terminus domain, destabilize RNA-PA subunit 
interaction ( Fodor, Mingay et al. 2003) underlying the significance of PA-C domain in intact genome viral replication.  
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1.2 Role of defective genomes (DGs) on viral pathogenesis  
 
Different RNA viruses produce defective genomes (DGs) as a direct product of viral replication, and their error prone 
polymerase. DGs have been detected in hospitalized patients infected with respiratory syncytial virus (RSV) and 
moreover their amount in clinical samples and activation of cellular antiviral response were positively correlated (Sun, 
Jain et al. 2015). Viral RNA replication and generation of DGs depend largely on viral polymerase and therefore single 
mutation in any of the subunits of the heterotrimeric influenza virus polymerase complex may affect its production. 
Our findings show that in vivo attenuated recombinant CAL-PB2 virus showed excessive production of DGs in cell 
culture, while more pathogenic recombinant viruses accumulated lower amounts of truncated viral RNAs in vitro 
(Figure 28). Both recombinant viruses with PA mutation (CAL-PA, CAL-PB2/PA) accumulated a reduced amount of DGs, 
which positively correlates with its pathogenicity in mice. However, the CAL-PB2/PA virus (with the F-like polymerase) 
generated twice as much defective vRNAs than CAL-PA virus which may indicate that influenza virus polymerase 
carrying PB2 A221T mutation generates excess of defective genomes during the infection and PA is able to partially 
decreased its production. This intermediate accumulation level of DGs in PAL-PB2/PA virus correlates with an LD50 
between CAL–PA and CAL-PB2 viruses. 
The control, CAL recombinant virus showed a very low accumulation of DGs in virions isolated from infected cells, 
which coincides with the reported high virulence of the CAL reference strain (Neumann et al., 2009), and is similar to 
the F virus (Figure 7 and 28). However, CAL was less pathogenic than CAL-PA recombinant in mice, suggesting that 
additional features to the total amount of DGs are involved in the different pathogenesis of these viruses. While most 
a b 
c 
Figure 34. PA-C and PB1 catalytic domain in tetrameric state of polymerase complex. (a, b) PA-C domain (purple) and PB1 
catalytic domain (yellow) presented from different perspective, unassigned helixes are presented in blue;  predicted PA-C 
domain (c) indicate β-6 and β-7 barrel (green) as critical features for RNA (light green and brown) binding. 310 helix and D529N 
are 10 aa prior to the β-6 barrel. (Shenghai Changatall at all. Molecular Cell, Issue5, 2015, 925–935) 
http://dx.doi.org/10.1016/j.molcel.2014.12.031 
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of the DGs generated by recombinant viruses carrying mutations in the viral polymerase were originated from PB1, 
PB2 and PA gene segments, as previously described (Dimmock and Easton 2014), the majority of DGs in CAL virions 
were originated from NS segment (Figure 29). This rare and exclusive distribution of DGs was similar in CAL-HA 
recombinant virus, which possesses an identical polymerase to that of CAL virus. Further analysis showed that the DGs 
from NS segment would synthesize a positive ssRNA with a deletion that would produce a NS1 protein without the 
RNA binding domain. Such a defective NS1 protein with impaired ability to counteract the antiviral response would 
decrease the virulence of these viruses (Garcia-Sastre, Egorov et al. 1998). The distribution of DGs per segment has 
been evaluated in virions isolated from infected cells; in more complex model such as infected mice this effect could 
be even more accentuated, exacerbating the decreased pathogenicity of these recombinants. Mice infected with 
these viruses would have lower viral titers in the lungs (Figure 16) due to stronger antiviral response which would lead 
to decreased inflammation processes in infected tissue, as we observed in our work (Table 8). Pathogenicity of the 
recombinants that do not possess mutations in viral polymerase (CAL and CAL-HA) correlates with this assumption. 
Since the high throughput sequencing has been performed in purified virions where viral mRNAs are not present, it is 
still unknown whether the positive ssRNA is actually transcribed from DG of the NS segment during infection and 
further experiments will be performed to evaluate this interesting hypothesis. Our observations suggest that not only 
quantity but also quality of generated DGs may affect the overall pathogenicity of influenza A viruses. 
1.2.1. Effect of PA D529N mutation on defective genomes accumulation during the infection 
 
The reference CAL/04/09 virus is one of the first, highly pathogenic clinical isolates of the 2009 pandemic outbreak 
(Itoh, Shinya et al. 2009, Swiss Institute of Bioinformatics). As mentioned, this virus has a low capacity of DGs 
generation, thus estimation of additional reduction of DGs generation by the introduction of a single PA D529N 
mutation in viral polymerase seems to be problematic. To circumvent this problem and have an experimental model 
that allows the examination of the role of the D529N mutation in PA polymerase subunit on DGs production in vitro, 
we used recombinant viruses with mutations in M viral segment that increase accumulation of DGs during the 
infection (Perez-Cidoncha, Killip et al. 2014). Recombinant viruses carrying mutations in M segment (CAL-M) and in 
both M and PA segments (CAL-M/PA) generate high amounts of DGs (Figure 31). Interestingly, recombinant CAL-M/PA 
virus, with M and additional PA D529N change, accumulated 4.6 folds less amount of DGs than the CAL-M 
recombinant. This data implies that D529N mutation in PA subunit decreases DGs generation in recombinant viruses 
with a high DGs generation capacity.  
PA D529N mutation does not affect viral polymerase activity (Figure 11), thus, the overall effect of this change on viral 
replication may be mediated by its decreased production of DGs, which may contribute to pathogenicity of CAL-PA 
recombinant virus in vivo. In addition to the ability of DGs production in infected cell, we observed that recombinant 
viruses were also able to produce DGs in in vivo infections (Figure 30). Although not very strict, there is certain 
correlation between in vivo pathogenicity and DGs generation, since more pathogenic recombinant viruses produce 
low amount of DGs, such as CAL and CAL-PA recombinants. To ascertain the relationship between DGs generation and 
in vivo pathogenicity we compared the pathogenicity of recombinant viruses with clearly distinguishable DGs 
production. Introduction of the M1+M2 mutations on the CAL or CAL-PA backgrounds, which generate high 
accumulation of DGs, leads to decreased virulence attenuation in mice (Figure 33b), as demonstrated by their 
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increased LD50. Besides viral attenuation of these two viruses, CAL-M-PA virus pathogenicity was greater than that of 
CAL-M virus, as indicated by body weight loss after sub lethal infection (Figure 335b). These data support the idea that 
reduced DGs accumulation is a pathogenic determinant for influenza virus in mice, and that mutation PA D529N 
derived from a fatal IAV case decreases DGs generation. DGs generation ability compared with replication of full-
length segments inversely correlates with pathogenicity in mouse model. One exception is represented by CAL-HA 
recombinant virus which was completely attenuated in mice although it did not accumulate DGs throughout infection. 
As mentioned, mutation in HA viral protein of CAL-HA recombinant virus may be a host range factor and therefore it 
can be completely attenuated in mice. Thus, we cannot exclude that the CAL-HA virus would have a different 
phenotype when expressed in a permissive animal model.  
Production of DGs has been correlated with morbidity and induction of antiviral response in patients infected with 
RSV (Sun, Jain et al. 2015) and mice infected with Sendai and influenza A virus (Tapia, Kim et al. 2013). Viruses with 
diminished ability to produce DGs have a delay in activation of cellular antiviral response independently of the origin 
of the virus. However, influenza virus capacity of DGs generation and their possible correlation with pathogenicity in 
humans has never been evaluated. Several studies in our laboratory carried out an unbiased approach to detect 
pathogenicity markers for highly pathogenic influenza viruses. To evaluate the role of accumulation levels of DGs in 
the pathogenicity of influenza viruses circulating in humans, next generation sequencing (NGS) was used to analyze 
viruses isolated from respiratory samples from a cohort of A(H1N1)pdm09-infected patients admitted to intensive 
care unit (ICU) or deceased (Severe-Fatal cohort).  For more precise characterization of the intrinsic pathogenicity of 
all these viruses, only those isolated from patients aged over 1 and under 65, and with no known comorbidities (only 
for  ICU admitted patients) were included (Figure 1A).  The cohort of ICU admitted patients is a faithful representation 
(80-100%) of the total confirmed fatal H1N1 influenza cases for these criteria in the 2013-2014 influenza season in 
Spain. These viruses were compared to those isolated from a cohort of IAV patients suffering mild symptoms (C, 
control).  
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Our study showed that the mean of DGs production of the severe-fatal (S-F) cohort (Figure 35), is lower than the mean 
of clinical isolates obtained from control patients (C). Curiously, the control viruses isolated from patients suffering 
mild symptoms showed DGs production from every viral segment, whereas some of the viruses isolated from S-F 
patients lack DGs from polymerase segments (data not shown). The evaluation of specific amino acids changes from S-
F viruses showed that changes affect different proteins. In addition, a small proportion of them did not show any 
amino acid change. The overall sequence analysis of these clinical strains did not give weight to any particular change 
in viral genome, but point out the lower nucleotide variability of strains isolated from the patients with a severe 
outcome, which accumulated fewer changes in the consensus sequence than strains isolated from control patients 
(database from NCBI) (manuscript under review). These results suggest that the low accumulation of DGs in S-F 
viruses might be mediated by different changes in distinct viral proteins, in the RNA structure, or by combinations of 
these elements. Additionally, these findings suggest that low DG abundance is a determinant of viral pathogenicity 
and has a role in the fatal outcome of influenza infection in humans independently of the amino acid or nucleotide 
changes responsible. Our results suggest quantitative determination of DGs as a prognostic marker for severe 
influenza disease.  
1.3 Role of host factors on viral pathogenesis  
 
Host factors may be important for pathogenicity in flu infections. Almost 300 host proteins have been involved in the 
early replication of influenza virus in mammalian cells, and many of them are involved in the highly delicate host-
pathogen interaction network (Konig, Stertz et al. 2010).  
Figure 35. Defective genomes accumulation. DGs accumulated in in vitro infections with viruses originated from patients with 
severe-fatal outcome (red) and mild (blue) clinical outcome.  DGs production by the F isolate (*); the M isolate (+);  and  the CAL 
recombinant virus (§). 
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Study of human host factors and its role in influenza infection, has been focal point of extensive research in our lab, 
with major interests in the ones involved in transcription and replication of influenza virus. We have described that 
various cellular factors interact with polymerase; hCLE/C14orf166 which not only interacts with vRNPs both in nucleus 
and cytoplasm of infected cells, but is also incorporated in the viral particle (Rodriguez-Frandsen, de Lucas et al. 2016); 
or NXP2/MORC3 that positively regulate influenza virus multiplication (Ver, Marcos-Villar et al. 2015). Several 
members of the CHD family of chromatin remodelers, CHD1 and CHD6, associate with viral polymerase and act as 
positive and negative modulator of influenza virus replication, respectively (Alfonso, Lutz et al. 2011, Marcos-Villar, 
Pazo et al. 2016). Also, host factors involved in protein translation such as the polyA binding protein 1 (PABP1) or the 
eIF4G have been characterized as interactors with influenza virus proteins. Recently, these host factors have been 
described as potential influenza antiviral targets (Rodriguez, Perez-Morgado et al. 2016).  
During 2009 pandemic, patients without any underlying medical conditions and similar health status suffered from 
different flu induced symptoms, ranging from mild illness to fatal outcome. Recent studies suggest that some genetic 
markers (SNP polymorphisms in inflammatory cytokines) could affect severity and final disease outcome in patients 
infected with influenza virus. The -238 A SNP (rs361525 A) allele of the TNF gene was described as risk factor for 
severe pneumonia (Antonopoulou, Baziaka et al. 2012, Garcia-Ramirez, Ramirez-Venegas et al. 2015) as well as IL6 
(rs1818879 GA) heterozygous genotype (Garcia-Ramirez, Ramirez-Venegas et al. 2015). Polymorphism in genes LTA 
(rs909253 AG), IL8 (rs4073 AA) contributes to disease severity in A(H1N1)pdm09 infected patients (Morales-Garcia, 
Falfan-Valencia et al. 2012) while IL1B (rs16944 AG and rs3136558 TC) SNPs decrease the risk of infection (Garcia-
Ramirez, Ramirez-Venegas et al. 2015). 
One of these genetic markers is CCR5∆32, a deleted form of Ccr5 gene, which is associated with influenza severity in 
patients (Falcon, Cuevas et al. 2015). C-C chemokine receptor (CCR5) is expressed on the surface of dendritic cells, 
macrophages, activated and memory T cells. HIV virus uses CCR5 receptor to target these immune cells and infect 
them. There are two alleles of Ccr5 gene in human population, a wild type CCR5 and CCR5Δ32 allele which possess 32 
base pair deletion that results in non-functional receptor. In HIV infection CCR5Δ32 heterozygous patients have slower 
progression of infection while homozygous patients show considerable resistance to some HIV subtypes (Liu, Paxton 
et al. 1996). In influenza virus infection, patients with one or both deleted alleles of the CCR5 receptor (CCR5Δ32 
homo- and heterozygous) were more susceptible to develop severe decease (Rodriguez, Falcon et al. 2013, Falcon, 
Cuevas et al. 2015). Interestingly enough, patient infected with F viral strain (HA S127L, PA D529N, PB2 A221T) was 
also homozygous for CCR5Δ32 allele, and thus the increased pathogenicity of the infecting virus and the genetic 
background of the patient may have cooperated in the fatal outcome of infection (Falcon, Cuevas et al. 2015). 
All these findings suggest that, besides viral, host factors play an important role not only in early stages of infection 
but also at later steps, contributing to pathogenicity and virulence of influenza A virus and affecting the course of 
disease and its progression in patients. 
1.4. Innate immune response contributes to viral pathogenicity in vivo  
 
Appropriate host response provides early line of defence, which affects the progression of the infection and the 
development of illness. Innate immune response as first strategy against viral pathogen serves to prevent, control and 
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eliminate infection and operates by induction of two major types of response; the inflammation and the antiviral 
defence. Antiviral defence is a process by which infected cells counteract the viral replication and became more 
susceptible to lymphocytes recognition. Inflammation response consists of leukocyte influx and circulating plasma 
proteins in the infected tissue and its activation in order to eliminate viral antigens. Acute inflammation, besides 
elimination of virus infection, induces tissue damage. That is why an adequate host immune response, disease 
tolerance and inflammation, greatly affect disease advance and its final outcome (Abbas, Lichtman et al. 2012).    
1.4.1 Antiviral cellular response 
 
Appropriate immune response (innate and adaptive) plays a key role in final outcome of infection. Sensing viral 
pathogen is a crucial step in the control of viral infection and development of illness. RIG-I is a major sensor of virus 
and therefore, essential in the control of viral infections. Upon the recognition of viral antigens, infected cells initiate 
several signalling cascades that induce intracellular antiviral and pro-inflammatory response. Antiviral response in 
infected cells induces transcription of type I interferons (IFN-α, β) which then activates transcription of interferon 
stimulated genes (ISGs) among them MxA and ISG56 (IFITM 1) proteins (Goodbourn, Didcock et al. 2000). These 
antiviral proteins suppress replication and transcription of viral genome in infected cells (Kochs and Haller 1999) and 
block viral entry (Bailey, Zhong et al. 2014), respectively.  Our results suggest that viruses with high DGs accumulation 
capability induce stronger antiviral response in early infection in vitro (Figure 26, 27a, b, and c) in accordance with 
previous study (Tapia, Kim et al. 2013). We observed that highly pathogenic CAL-PA recombinant virus induces lower 
transcription of MxA and ISG56 antiviral genes (Figure 27a, b) at the very beginning of infection. These differences 
disappear after the end of the first viral cycle.  Differences in activation of antiviral response at early times of infection 
may be explained by the dissimilar capability for DGs generation of the different recombinant viruses. Pattern 
recognition receptor, RIG-I possesses a high binding affinity for short, ssRNA molecules (Kato, Takeuchi et al. 2008) 
such are DGs molecules up to 1000 nt long. This recognition activates signal cascades that terminate in IFN-α/β 
dependent activation of antiviral gene transcription. Induction of IFN-β transcription, in infection with more 
pathogenic recombinant viruses (CAL, CAL-PB2/PA and CAL-PA), does not correlate with ISG56 and MxA expression at 
early stage of infection (Figure 27). This may indicate that IFN-β is not the prominent inducer of antiviral gene 
transcription in viral infections with these recombinant viruses. Since IFN-λ have been described as one of the crucial 
activators of antiviral response in influenza infection in both cell culture (Wang, Oberley-Deegan et al. 2009) and 
mouse model (Kim, Kim et al. 2016), IFN-λ may be the actual activators of antiviral gene transcription. However, 
further experiments will be required to evaluate this proposed data. 
As previously mentioned, not just the quantity but also the quality of DGs may affect overall antiviral response in 
infected cells. Our reference, CAL recombinant virus generates the same amount of DGs as the highly pathogenic CAL-
PA virus, yet induces higher antiviral response than CAL-PA at early stage of infection. Having in mind that CAL 
recombinant virus produces DGs almost exclusively originated from NS segment, which would correspond to defective 
NS1 mRNA, it would imply that CAL recombinant virus with certain amount of non-functional NS1 protein would not 
be able to efficiently impair antiviral response (Gack, Albrecht et al. 2009) and therefore, will induce more ISG56 and 
MxA than CAL-PA virus.  
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Considering these data in more complex in vivo system, a hampered sensing of early viral infection by the involved 
cellular sensors will delay the activation of appropriate antiviral response and will promote immune tolerance to 
infection, allowing higher viral replication rates in early infections. On the flip side, uncontrolled viral growth would 
lead to enormous viral burden that would induce excessive inflammation process, which would clearly contribute to 
pathogenicity of the virus.  
1.4.2 Cellular innate immune response (cell influx and inflammation) 
 
Upon influenza infection, both immune response of the host and the nature of the viral strain are very important for 
the final outcome. Inadequate host innate immune response, severe cell influx, inflammation (pro-inflammatory 
cytokine storm) or immune tolerance to pathogen that leads to massive viral growth, could lead to fatal outcome. In 
viral infections, neutrophils and alveolar macrophages play a key role in clearance and control of viral growth in 
infected lungs, thus their substantial influx in infected tissue contributes to overall viral pathogenicity. Depletion of 
alveolar macrophages leads to an uncontrolled viral proliferation and fatal outcome in infected mice (Tumpey, Garcia-
Sastre et al. 2005) while high influx of neutrophils in lungs and excessive inflammation has been associated with 
severe illness and high mortality rate in influenza infection (Brandes, Klauschen et al. 2013). Therefore, excessive 
innate immune response and inflammation is observed in infection with highly pathogenic viral strains.  
We found that recombinant viruses with PA D529N change (CAL-PA and CAL-PB2/PA) induce high infiltration of cells of 
innate immune response in lungs of infected animals (Figure 22-25) as well as severe inflammation (Table 8) caused by 
overexpression of chemokines, pro-inflammatory cytokines on the 2
nd
 day of infection. Biomarkers of acute 
inflammation processes in lungs of patients with chronic obstructive pulmonary disease (COPD) (Calero, Arellano et al. 
2014) were highly expressed in lung of CAL-PA infected mouse suggesting severe pulmonary damage in infected 
animal. Alveolar macrophages showed significant depletion on the 2
nd
 day of infection (Figure 23) in CAL-PA infected 
lungs which was a general feature for all previously described pathogenic recombinant viruses (Table 6). This 
depletion of alveolar macrophages perfectly correlates with increased viral titers in lung tissue of infected animals 
(Figure 16), emphasizing again the crucial role of these cells in viral clearance and control of viral growth.  Our findings 
show that CAL-PA virus is a potent inductor of innate immune response (cellular influx) and extensive inflammation 
process in infected lungs, which greatly contributes to its pathogenicity in vivo. Since it has been described that PA 
subunit of viral polymerase is one of the markers of pathogenicity of influenza A viruses as well as an inducer of strong 
innate immune response and inflammation of infected lungs (Hu, Hu et al. 2013), PA D529N change in polymerase 
complex may enhance severe host innate immune response (cell influx and inflammation). Both viruses that contain 
this mutation (CAL-PA and CAL-PB2/PA) have similar influx of innate immune cell response although they do not have 
the similar viral load (Figure 16) on the same day of infection (2
nd
dpi). Therefore, immune response detected in 
animals infected with these viruses does not correlate with observed lung viral titer in these animals. What is more, 
CAL-PB2/PA has similar viral growth in infected lungs as CAL recombinant virus (Figure 16), while animals infected with 
these recombinants have a completely different cell influx innate immune response (Figure 22-25). Together, these 
data suggest that D529N change in PA viral polymerase subunit is responsible for increased induction of innate 
immune response (cellular influx) and extensive inflammation process independently of viral burden in infected lungs.  
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Since viruses with D529N mutation in PA subunit of viral polymerase induce strong innate immune response and 
inflammation in infected animals independently of its high growth capability in lungs, high viral growth in vivo might 
not be solely dependent of the mutation found in PA subunit but trough depletion of alveolar macrophages in infected 
lungs (Figure 23) as well. Alveolar macrophages, besides pneumocytes and dendritic cells (Hartmann, Thakar et al. 
2015), are the infectious target of highly pathogenic influenza strains (Kasloff and Weingartl 2016), and its prominent 
infection can compromise viral and tissue damaged clearance, as well as adequate early innate immune response 
(Chang, Kuchipudi et al. 2015, Halstead and Chroneos 2015).   
Therefore, high viral titers observed in recombinants with PA D529N change may depend on various factors that 
contribute to high viral growth in infected lungs. Initial delay in antiviral cellular response in very early stage of 
infection may allow unhampered viral growth in infected cells. As a consequence of low antiviral cell state and 
undisturbed viral growth in early infection, neighbouring pneumocytes as well as alveolar macrophages and other cells 
involved in fast viral infection response would not only suffer a delay in activation of innate cellular immune response 
but also become an easy viral targets in first hours of infection. However, after the first several hours of infection, in 
later stages of infection extreme viral burden would provoke potent and vigorous immune response causing severe 
cell influx, acute inflammation and serious and massive damage in infected tissue. This infection pattern precisely 
corresponds to our observations obtained in the murine infection model with PA D529N mutant viruses.  
1.5 Viral spread promotes viral pathogenicity in vivo 
 
Viral spread represents an important aspect of overall pathogenicity of any influenza viral strain. In critically ill 
patients several clinical complications have been associated with cardiac abnormalities (Jeyanathan, Overgaard et al. 
2013), renal (Watanabe 2013) and neurological (Frobert, Sarret et al. 2011) difficulties. Influenza infection in some 
fatal cases induces different heart complications, inflammation in hearts, presence of the viral particles in this organ 
(Komai, Nakazawa et al. 2011, Jeyanathan, Overgaard et al. 2013) and severe hypoxemia in patients in critical medical 
condition (Quddus, Afari et al. 2015). Very common complication of A(H1N1)pdm09 infections were transient and 
reversible cardiac dysfunctions (Martin, Hollingsworth et al. 2010), which emphasizes the capability of viral spread of 
influenza A virus as a pathogenicity marker. Furthermore, infection of mice with pathogenic A/Puerto Rico/8/34 strain 
leads to heart infection that induces inflammation in this organ as well as presence of viral particles up to 9 days upon 
the infection (Pan, Sun et al. 2014).  
Using recombinant viruses containing specific mutations in the viral polymerase, we showed that infection with CAL-
PA recombinant results in high viral titers in infected mice lungs during the first four days of infection (Figure 16). 
Interestingly enough, apart from usual influenza infection symptoms such as weight loss, shivers, lethargy, etc. we 
observed a phenomenon of sudden death at very early stage of infection (3dpi) in CAL-PA infected mice with high viral 
doses (10
6
 and 3x10
5
 pfu). Sudden death usually occurs from cardiac causes, and here we have detected presence of 
viral particles due to genuine replication in heart tissue. Incidence of hearts positive for viral particles detection of 
animals infected with CAL-PA virus sums up to 80% by the 4
th
 day of infection (Figure 19). This result indicates that 
CAL-PA recombinant virus has stronger capability for heart infection than other recombinant viruses.  Sample 
contamination was discarded as origin of viral presence in the heart since the heart titers do not correlate or depend 
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on the replication in lungs (Figure 21); for instance some mice having high viral titers in lung do not present infectious 
particles in the hearts. Therefore, persistent and prolonged heart infections as well as ongoing viral replication in 
heart tissue in early infection contribute to pathogenicity of CAL-PA virus, especially having in mind that viral doses 
used for this infection assay are sub lethal.  
To evaluate whether viral presence in the heart could induce a physiological cardiac damage, we have conducted a 
preliminary study in collaboration with cardiologists from Centre for Arrhythmia Research at university of Michigan, 
College of Medicine Cardiology at University of South Florida, and CNIC, Madrid. Electrocardiogram (ECG) was 
monitored on mock-infected animals and mice infected with high viral doses (10
6
 pfu) of CAL-PA or CAL-PB2 
recombinant virus for 4 days after infection and compared with their own uninfected cardiac status.  The ECGs 
analysis shows that animals infected with both viruses suffered from bradycardia. Additionally, only those animals 
infected with CAL-PA recombinant virus (Figure 36) showed cardiac conduction defects, which correlate with viral 
particles presence in hearts all throughout the infection. Further studies would give us more insights into influenza 
virus effect on heart conduction system as well as its effect on progression of disease and final outcome. 
 
Another virus with positive sense ssRNA genome, the Coxsackievirus B (CVB), affects heart tissue and causes 
myocarditis, which might be associated with heart failure and left ventricular dysfunction. Infection and replication of 
this virus induces cardiomyocytes injury and activates maladaptive inflammatory responses (Garmaroudi, Marchant et 
al. 2015). 5´ deletions of RNA genome of CVB found in serial passages in vitro as well as in vivo (infected mice hearts) 
affects viral replication in infected cells by accumulation (–) RNA genome (Kim, Chapman et al. 2008). Persistence of 
defective genome was detected 5 months upon viral infection in mice, without the necrotic effects typically observed 
during infection with virus with intact genome (Kim, Tracy et al. 2005). Deletions in viral genome allow CVB to persist 
in the resident tissue expressing non-cytolytic phenotype and prolonging lower inflammatory response than viruses 
with intact RNA genome. A similar mechanism may operate in influenza virus heart infection. CVB induces fulminant 
myocarditis in patients, which causes several heart dysfunctions by induction of tissue damage; influenza virus 
Figure 36. Representative electrocardiogram of control or flu infected animals. a) Cardiac rate of an uninfected animal on the 
2
nd
 dpi. (b) Cardiac rate of two representative animals infected with high viral dose (10
6
 pfu) of CAL-PA recombinant virus on the 
2
nd
 dpi, in which enhanced systolic bradycardia and conduction disorders have been observed. 
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infection may have the same modus operandi.  CAL-PA recombinant virus infects and replicates in heart tissue of 
infected mice, and induces excessive innate immune response and severe inflammation in infected lungs. Moreover, 
this recombinant virus possesses a mutation in the PA subunit of viral polymerase that affects production of DGs and 
overall viral replication fidelity, allowing CAL-PA virus to replicate more efficiently (production of intact full length 
segments) than other recombinant viruses. High viral replication and persistence of this virus in heart tissue (Figure 20 
and 21) may induce severe myocarditis in infected animals and cause phenomenon of sudden death that we 
observed. Furthermore, our findings suggest that influenza A virus can infect Purkinje fibers in heart besides 
cardiomyocytes. Preliminary analysis of histological samples of heart tissue of mice infected with clinical isolate from a 
deceased patient, F virus, seem to indicate that along with cardiomyocyte, Purkinje fibers were also infected with 
influenza virus. Normal heart sinus rhythm is maintained by natural heart pacemakers sinoatrial (SA node) and 
atrioventricular (AV node) nodes and Purkinje fibers. Dysfunction of pacemaker cells in the nodes or Purkinje fibers 
causes irregular heart rhythm and viral infection of these cells may provoke abnormal heart rhythm (arrhythmia). 
Further investigation regarding influenza virus heart infection and its mechanisms are necessary in order to complete 
understanding of this complex process.  
As it was mention before, pathogenicity of any viral strain is a multifactorial process that depends on various viral and 
host factors as well as delicate interplay between them. In our study we showed that a single mutation in the viral 
polymerase complex can affect several aspects of in vivo infection.  D529N change in PA polymerase subunit allowed 
high viral growth in the lung of infected mice, induced stronger innate immune response and enhanced high viral 
replication and persistence in hearts of infected animals. Mutation PA D529N was detected in a clinical strain isolated 
from a deceased patient and may be a key factor to pathogenicity of H1N1 influenza A virus in humans. 
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Conclusions 
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1. A221T aa change in PB2 subunit of the viral polymerase is an attenuating factor in the context of an Influenza 
A(H1N1)pdm09 virus in in vivo model. 
 
2. S127L aa change in HA surface glycoprotein does not contribute to virulence of the F virus isolated from a 
fatal case and it may be considered a host restrictive range factor for mice. 
 
3. Introduction of PA D529N aa change in A/California/04/09 strain backbone virus decreases almost 100-fold 
LD50 in vivo. 
 
4. D529N aa change in PA subunit of the viral polymerase is the major contributor to the high pathogenicity of 
the F virus isolated from a fatal case. 
 
5. Recombinant virus containing PA D529N aa change confers virulence and pathogenesis through:  
 
o low accumulation of DGs during in cell culture infections  
 
 
o low induction of antiviral response in very early stage of cell culture  infection  
 
 
o high viral replication in the lungs of infected animals 
 
 
o excessive innate immune cell influx (neutrophils and presumably conventional dendritic cells) and 
acute inflammation observed in lungs of animals infected with sub lethal viral doses  
 
o higher replication and prolonged presence of infectious viral particles in hearts of infected animals 
which seems to be associated with cardiac disorders observed in infected animals  
 
6. Decreased accumulation of defective genomes found in A/California/04/09 recombinant viruses containing 
PA 529N (CAL-PA, CAL-PB2/PA, CAL-M/PA) confers increased pathogenicity in the mice model, which is in 
accordance with pathogenic viral phenotype of natural viral isolates found in hospitalized patients with 
severe-fatal outcome. 
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1. El cambio de aa A221T en la subunidad PB2 de la polimerasa viral es un factor de atenuación en el contexto 
de un virus  de la gripe A(H1N1)pdm09 en un modelo in vivo. 
 
2. El cambio de aa S127L en la glicoproteína de superficie HA, no contribuye a la virulencia del virus F aislado de 
un caso fatal y puede considerarse un factor de rango de huésped en ratón. 
 
3. La introducción del cambio D529N en la subunidad PA en la cepa A/California/04/09 disminuye casi 100 veces 
la LD50 in vivo. 
 
4. El cambio de aa D529N en la subunidad PA de la polimerasa viral supone la mayor contribución a la alta 
patogenicidad del virus F aislado de un caso fatal. 
 
5. El cambio de aa PA D529N en un virus recombinante confiere virulencia y patogenicidad a través de: 
 
o baja acumulación de DGs durante la infección en células en cultivo 
 
o baja inducción de respuesta antiviral en estadios muy tempranos de la infección en células en cultivo 
 
o alta replicación viral en los pulmones de los ratones infectados 
 
o excesivo reclutamiento (neutrófilos y presumiblemente células dendríticas convencionales) e inflamación 
aguda observada en los pulmones de los ratones infectados con dosis subletales 
 
 
o alta replicación y presencia prolongada de partículas virales en los corazones de los animales infectados, 
lo que parece estar asociado con desordenes cardíacos observados en animales infectados 
 
 
6. La disminución de genomas defectivos encontrada en virus recombinantes A/California/04/09 conteniendo 
PA D529N (CAL-PA, CAL-PB2/PA, CAL-M/PA) confiere patogenicidad incrementada en el modelo de ratón, lo 
que está de acuerdo con el fenotipo de patogenicidad encontrado en aislados virales de pacientes 
hospitalizados con un desenlace severo-fatal. 
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